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https://doi.org/10.1016/j.cell.2020.05.053SUMMARYOncogenic transformation is associated with profound changes in cellular metabolism, but whether tracking
these can improve disease stratification or influence therapy decision-making is largely unknown. Using the
iKnife to sample the aerosol of cauterized specimens, we demonstrate a new mode of real-time diagnosis,
coupling metabolic phenotype to mutant PIK3CA genotype. Oncogenic PIK3CA results in an increase in
arachidonic acid and a concomitant overproduction of eicosanoids, acting to promote cell proliferation
beyond a cell-autonomous manner. Mechanistically, mutant PIK3CA drives a multimodal signaling network
involving mTORC2-PKCz-mediated activation of the calcium-dependent phospholipase A2 (cPLA2).
Notably, inhibiting cPLA2 synergizes with fatty acid-free diet to restore immunogenicity and selectively
reducemutantPIK3CA-induced tumorigenicity. Besides highlighting the potential for metabolic phenotyping
in stratified medicine, this study reveals an important role for activated PI3K signaling in regulating arachi-
donic acid metabolism, uncovering a targetable metabolic vulnerability that largely depends on dietary fat
restriction.INTRODUCTION
In addition to the routine use of histological subtyping in cancer
diagnosis and therapy decision-making, a renewed interest has
emerged in the identification of novel predictive factors to
improve patient stratification and therapeutic response. Malig-
nant transformation and disease progression involve multiple
changes in biosynthetic and energy production pathways, offer-
ing opportunities to exploit the clinical utility of metabolic1596 Cell 181, 1596–1611, June 25, 2020 ª 2020 The Author(s). Publ
This is an open access article under the CC BY-NC-ND license (http://tracking in diagnosis and disease monitoring (Vander Heiden
and DeBerardinis, 2017). Cells can also reprogram pathways
of nutrient acquisition and processing as a result of oncogenic
activation of commonly perturbed signaling pathways (Tar-
rado-Castellarnau et al., 2016). A characteristic example is the
activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) pathway, which
regulates a wide range of transcriptional and post-translational
programs to support the anabolic and catabolic requirementsished by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
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OPEN ACCESSArticleof proliferating cells (Carracedo and Pandolfi, 2008; Dibble and
Manning, 2013; Fruman et al., 2017; Lien et al., 2016).
These observations raise some fundamental questions:
whether we can use metabolic tracking for more effective
screening of the molecular features underlying tumor pathogen-
esis and, ultimately, whether this information can be translated
into better and more efficacious treatment strategies for each
patient. Indeed, the concept of metabotyping has been widely
applicable in characterizing functionally distinct traits that have
the power to influence clinical decision-making (Gavaghan
et al., 2000; Holmes et al., 2008; Nicholson et al., 2002, 2012).
Here, we used rapid evaporative ionization mass spectrometry
(REIMS), which coupled to the intelligent surgical device, also
known as iKnife, allows for instantaneous chemical analysis of
the aerosol generated during electrosurgical tissue ablation
and cauterization, in the form of gas-phase ionic species. Unlike
other technologies that are commonly used for metabolite
profiling, such as liquid chromatography-mass spectrometry
(LC-MS), REIMS analysis requires no sample preparation and al-
lows for near real-time (1–2 s) lipidomic analysis and tissue
recognition, based on multivariate classification analysis of
spectral libraries of reference mass spectra.
The iKnife/REIMS can be used both in the intraoperative and
biopsy collection settings to differentiate cancerous from non-
cancerous tissues with very high precision, based on their lipido-
mic composition (Alexander et al., 2017; Balog et al., 2013; St
John et al., 2017). However, the potential of using this technology
beyond the pattern-level identification of tissues, to reveal the
biological mechanisms underlying unique metabolic signatures,
or identify which patients will likely benefit from a given treat-
ment, has not yet been explored.
RESULTS
Metabolic Phenotyping Using REIMS PredictsMolecular
Markers Including Oncogenic Mutations in PIK3CA
We first examined whether REIMS-detected lipid signatures
correlate with any established molecular markers of breast can-
cer of known prognostic and therapeutic value (Figure 1A). For
this, we selected a panel of 43 breast cancer cell lines, 18 pa-
tient-derived xenograft (PDX), and 12 primary breast tumors
that are well characterized for their estrogen (ER), progesterone
(PR), and HER2 receptor status. REIMS profiling of cell lines
consistently classified ER, HER2, and triple negative status
(TN) with area under the curve (AUC) accuracies between 0.8–
0.9, and 0.6–0.7 for PR (Figure 1B).
Consistent with previous studies (Hilvo et al., 2011), the most
striking differences in lipid profiles were observed between ER-
positive (+ve) and -negative (ve) breast cancer cell lines (Fig-
ures 1B and S1A; Table S1) and tumor specimens (Figure S1B).
A surrogate marker for ER positivity, aside from its routine deter-
mination by immunohistochemistry (IHC), is expression of the
estrogen receptor 1 (ESR1) gene. We built a regression model
to predict ESR1 expression based on the spectral profiles ob-
tained by REIMS and tested this in representative ER+ve cell lines
treated with or without 4-hydroxy-tamoxifen (4-OHT). Of note,
the predicted ESR1 expression was significantly reduced
following 4-OHT treatment as compared to untreated controls(Figures 1C and S1C), suggesting that the modulation of ER
signaling induces distinct lipidomic alterations, which are detect-
able by REIMS and are reversible by ER inhibition.
With a robust lipidomic profile obtained using REIMS, we
next performed unsupervised hierarchical clustering to partition
all breast cancer cell lines on the basis of their spectral similar-
ities measured over 872 lipid species. This analysis revealed
two subtypes with distinctive signatures, in which REIMS-de-
tected lipid species were significantly enriched (black) or
depleted (gray) (Figure 1D). The observed clusters were also
confirmed using a consensus non-negative matrix factorization
(NMF) (Figure S1D).
To shed light on the mechanism that is driving this unique
metabolic classification, we examined mutational enrichment
of the cells between the two subtypes. Out of the top 150 genes
that are frequently (>20%) mutated in these cell lines, oncogenic
mutation in PIK3CA was the only one to be significantly (Fisher’s
test, p value = 0.019) overrepresented in the lipid-enriched clus-
ter (Figure 1E; Table S2). In accordance with this finding, analysis
of isogenic MCF10A PIK3CA wild-type (WT) and mutant (MUT)
(E545K and H1047R) cell lines also revealed clustering of the
latter in the lipid-enriched group, both when cells were cultured
in 2D, or 3D as spheroids (Figures 1E and S1E). Consistent with
this stratification, performing gene and functional pathway
enrichment analyses revealed KEGG-pathway ontologies
relating tometabolic pathways that were significantly associated
with the lipid-enriched subtype (Figures S2A and S2B). Specific
overexpressed genes included FASN and ELOVL6, which are
involved in de novo lipogenesis, and LDLRAP1, which facilitates
exogenous lipid uptake (Figures S2C–S2E). Indeed, PIK3CA
MUT cells displayed elevated induction of the de novo lipogen-
esis transcriptional regulator SREBP1 (Figure 1F) and higher
exogenous FA uptake capacity (Figure 1G), suggesting that
both could contribute to the lipid-enriched metabotype.
Most importantly, the observed metabolic stratification was
also evident among PIK3CA WT and MUT breast cancer PDXs
(Figure 1H) and primary tumors (Figure 1I; Table S3). Among
the PDX tumors assessed (n = 18), only one was misclassified
(BR5017), and this harbored a rare I391M mutation that has ac-
tivity reminiscent of WT PIK3CA (Dan et al., 2010) (Figure 1H).
Overall, PIK3CAmutation status in both PDX and primary tumors
could be classifiedwith an accuracy of 90%using all measurable
lipid species (Figure S1F), suggesting that the iKnife/REIMS
could be used for near real-time diagnosis of PIK3CA MUT
breast cancers by MS analysis of aerosolized tissue material.
mTORC2 Signaling Downstream of Oncogenic PIK3CA
Drives the Lipid-Enriched Phenotype
The effects of PI3K/Akt/mTOR signaling on lipid metabolism have
been observed on numerous levels (Dibble and Manning, 2013;
Lien et al., 2016; Saxton andSabatini, 2017). To elucidate the spe-
cificmechanisms underlying the observed phenotype, we treated
PIK3CAMUT cells with inhibitors targeting the activity of key no-
des in the PI3K pathway (Figure 2A), albeit at concentrations that
do not affect cell viability (Figure S3A). PI3K (BYL719, BKM120)
and mTOR (rapamycin, torin 1) inhibition dramatically reduced
relative phospholipid levels, but surprisingly, Akt inhibition with
either MK2206 or GSK690693 did not (Figure 2B). Similar resultsCell 181, 1596–1611, June 25, 2020 1597
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Figure 1. REIMS Analysis Predicts Breast Cancer Molecular Markers Including Oncogenic Mutations in PIK3CA
(A) Schematic overview of sample preparation for REIMS analysis.
(B) Area under the curve (AUC) classification accuracies for ER, PR, HER2 receptor, and triple negative status of 43 breast cancer (BC) cell lines (median intensity
of n = 3 biological replicates) following feature selection for phospholipids in the m/z range 600–900, and leave-one-out cross validation.
(C) Immunoblot analysis of estrogen inducible protein pS2 and predicted ESR1 expression in ER+ve MCF7 cells following treatment with 0.1%DMSO or indicated
concentrations of 4-OHT for 72 h.
(D) Unsupervised hierarchical clustering of 872 lipid species detected by REIMS across 43 BC cell lines.
(E) Dendrogram of BC cell lines and isogenic MCF10A cells harboring either WT or MUT (E545K or H1047R) PIK3CA.
(F) Immunoblot analysis of mature SREBP1 transcription factor expression in nuclear extracts of the MCF10A PIK3CA isogenic panel.
(G) Relative exogenous fatty acid uptake in MCF10A PIK3CAWT andMUT cells following serum starvation for 1 h and supplementation with fluorescently labeled
dodecanoic acid (n = 5 replicates).
(H and I) Unsupervised hierarchical clustering of 9 PIK3CAWT and 9MUT breast PDX tumors (H) and (I) 5WT and 7MUT primary breast tumors. Individual rows in
the heatmaps in (D), (H) and (I) correspond to scaled Z score phospholipid intensities (n = 3 biological replicates). Error bars represent ± SEM. n.s., not significant;
*p% 0.05; **p% 0.01; ***p% 0.001. p values in (C, bottom panel) and (G) were calculated with one-way ANOVA, followed by unpaired, two-tailed Student’s t test
with Bonferroni correction.
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Figure 2. Oncogenic PIK3CA Drives the Lipid-Enriched Phenotype via mTORC2 Signaling
(A) MCF10A PIK3CA MUT cells were treated with BYL719 or BKM120 (100 nM), MK2206, or GSK690693 (150 nM) for 72 h, or rapamycin (20 nM) for 4 h, or
rapamycin or torin 1 (20 nM) for 72 h.
(B) Unsupervised hierarchical clustering of MCF10A E545K and H1047R MUT cells treated with PI3K, AKT, and mTOR inhibitors.
(C andD) Immunoblot analysis (C) and unsupervised hierarchical clustering (D) ofMCF10A E545K andH1047R cells transfected withRAPTOR,RICTOR, ormTOR
siRNA. Individual rows in the heatmaps in (B) and (D) correspond to scaled Z score phospholipid intensities (n = 3 biological replicates).
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lines, with the exception of MCF7 cells that also responded to
MK2206 (Figure S3B).
Interestingly, we did not observe an effect on relative phos-
pholipid abundances following acute exposure to rapamycin
for 4 h, despite inhibition of mTORC1 (Figures 2A, bottom left
panel, and 2B). Because extended rapamycin treatment inhibits
mTORC1 and mTORC2 (Figure 2A, bottom right panel) (Sarbas-
sov et al., 2006), and both impinge upon lipogenesis (Du¨vel et al.,
2010; Griffiths et al., 2013; Guri et al., 2017; Lee et al., 2017;
Ricoult et al., 2016), we sought to investigate which of these
complexes might contribute to the regulation of the observed
phenotype. Knockdown of RICTOR or mTOR, but not RAPTOR,
led to a significant reduction in relative phospholipid abun-
dances (Figures 2C and 2D), pointing to a PIK3CA- and
mTORC2-dependent metabolic phenotype that is largely inde-
pendent of mTORC1 or Akt inhibition.
Oncogenic PIK3CA Drives Enhanced Arachidonic Acid
Metabolism, thereby Promoting Cell Proliferation
beyond a Cell-Autonomous Manner
Given that global lipidomic profiles could stratify breast cancer
cell lines and tumors based on PIK3CA mutation status, we
next aimed to characterize specific lipid alterations that are
associated with oncogenic PIK3CA. Fatty acids (FAs), which
are the main constituents of phospholipids and have additional
effector functions in cancer pathogenesis, were profiled in the
PIK3CA isogenic panel using REIMS. Among the most abundant
FAs in PIK3CA MUT compared to WT cells were palmitoleate
(FA16:1), palmitic acid (FA16:0), and oleic acid (FA18:1), all ofwhich are established products of elevated lipogenesis and in
line with the observed lipid enriched phenotype (Figure 1D; Table
S4). Interestingly, the secondmost significantly elevated FA after
palmitoleate was arachidonic acid (AA) (FA20:4), an omega-6 FA
which is predominantly found in animal fats and is of particular
relevance as a major regulator of pro-inflammatory responses
in cancer, through the production of bio-active lipids known as
eicosanoids (Wang and Dubois, 2010) (Figure 3A; Table S4).
Importantly, in addition to the cell lines, significant elevations in
AA were also observed in all the PIK3CA MUT breast PDX and
primary tumors (Figures 3B and 3C) and across tumors of other
tissue types including ovarian, pancreatic, and sarcomas (Fig-
ure 3D). In agreement with our REIMS findings, AA and down-
stream eicosanoids were also found to be significantly elevated
in both PIK3CA MUT cells using LC-MS (Figures 3E, S4A,
and S4B).
To measure FAs that are secreted from cells, as opposed to
those that might already exist in serum-supplemented media,
cells were grown under FA-deprived conditions. Pro-inflamma-
tory derivatives of AA were significantly increased in the media
of PIK3CA MUT cells (Figure 3F), signifying a potential role for
these bio-active lipids in tumor microenvironment (TME)
interactions.
Next, to ascertain the functional consequences of elevated
eicosanoid metabolism, the effects of PIK3CA MUT-derived
conditioned media (CM) were assessed. PIK3CA WT cells dis-
played dramatically increased proliferative rate following incuba-
tion with CM obtained from MUT cells, and this was effectively
rescued by depleting the lipids from the media (Figures 3G,
S4C, and S4D). Moreover, the proliferation of both PIK3CACell 181, 1596–1611, June 25, 2020 1599
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Figure 3. Oncogenic PIK3CA Drives Enhanced Arachidonic Acid Metabolism
(A and B) Arachidonic acid (AA) levels measured by REIMS in MCF10A PIK3CA WT and MUT cells cultured under full 5% horse serum or fatty acid-free (FAF)
conditions for 72 h (n = 3 biological replicates) (A). AA levels of 18 breast PDX tumors (n = 9 PIK3CAWT and n = 9 MUT) (left) (B). Three sections corresponding to
different tumor regions were analyzed with REIMS. Data are summarized in the boxplot to the right.
(C) 12 primary breast tumors (n = 5 PIK3CA WT and n = 7 MUT) (left). Data are summarized in the boxplot to the right.
(D) Breast, ovarian, pancreatic, sarcoma, and colorectal PDX tumors (n = 5 PIK3CAWT and MUT tumors for breast, pancreatic, sarcoma, and colorectal tissues,
and n = 4 PIK3CA WT and MUT ovarian PDX tumors).
(E) Heatmap and Venn diagram summarizing the intracellular eicosanoids that were significantly different between MCF10A PIK3CA WT and MUT cells. Rows
correspond to the Z score scaled eicosanoid intensities detected by LC-MS (n = 3 biological replicates).
(F) Heatmap and Venn diagram summarizing the eicosanoids of the conditioned media (CM) that were significantly different between MCF10A PIK3CAWT and
MUT cells.
(G) Cell proliferation assays of MCF10A PIK3CAWT cells cultured in CM derived fromWT or H1047RMUT cells before or after lipid depletion (LD), with or without
the supplementation of 25 mM AA, palmitate, or palmitoleate.
(H) Cell proliferation assays of MCF10A PIK3CA H1047R MUT cells before or after LD, with or without the supplementation of 25 mM AA, palmitate, or palmi-
toleate. Sulforhodamine B (SRB) protein staining was used in (G) and (H) tomeasure cell proliferation over 5 days (replicates from n = 3wells). Error bars in (G) and
(H) represent mean ± SEM for each time point. *p% 0.05; **p% 0.01; ***p% 0.001. p values in (A)–(D) were calculated with unpaired, two tailed Student’s t test.
Two-way ANOVA was used for (G) and (H).
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OPEN ACCESS ArticleMUT cell lines was significantly reduced following incubation
with their respective lipid-deprived CM (Figures 3H and S4E),
whereas supplementation of lipid-deprived CM with AA, but
not palmitate or palmitoleate, restored proliferation in both WT
and MUT cells (Figures 3G, 3H, S4D, and S4E). Together, these1600 Cell 181, 1596–1611, June 25, 2020data support not only a critical role for oncogenicPIK3CA in influ-
encing autocrine- and paracrine-mediated cell proliferation, but
also point to AA as an easily measured metabolic biomarker that
could help with the diagnosis and treatment of PIK3CA MUT
tumors.
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Figure 4. Oncogenic PIK3CA Signaling Triggers cPLA2-Induced Arachidonic Acid Production
(A) Enzymatic activity of cPLA2, iPLA2, and sPLA2 in the MCF10A PIK3CA isogenic panel.
(B–D) cPLA2 activity (B) and AA levels (C and D) measured by REIMS in MCF10A H1047R PIK3CA MUT cells following RAPTOR or RICTOR siRNA-mediated
knockdown (C), or treatment with 100 nM ASB14780, 1 mM each of PKCa, b, ε, or z peptide inhibitors, 250 mMGSK650394, or 150 nMMK2206 for 72 h (D). Cells
were grown under exogenous FAF conditions.
(E) cPLA2 activity following PKCz inhibition with 1 mM peptide inhibitor for 72 h.
(legend continued on next page)
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Acid Production via mTORC2-PKCz-cPLA2 Signaling
To better understand the mechanism by which PIK3CA MUT
cells have elevated AA, we assessed various pathways which
contribute to its cellular pool, including: direct exogenous up-
take, synthesis from linoleic acid, hydrolysis from diacylglycerol
(DAG), or endogenous release from membrane phospholipid
through phospholipase (PLAs) activity. Curiously, we noted a
persistent increase in AA in PIK3CA MUT isogenic panel even
when cells were cultured with FA-free media (Figure 3A). Addi-
tionally, DAG levels—that can be in part generated from the hy-
drolysis of phosphatidylinositol-4,5-bisphosphate (PIP2)—were
significantly reduced in PIK3CA MUT cells (Figures S4F
and S4G).
These results pointed to a potential role for phospholipases
(PLAs), of which three main classes predominate: cytosolic/cal-
cium-dependent (cPLA2), calcium-independent (iPLA2), and
secretory (sPLA2) phospholipase A2 (Burke and Dennis, 2009).
Among these, only cPLA2 displayed significantly higher enzy-
matic activity (Figure 4A), as well as elevated total protein levels
and stability (Figures S5A and S5B) in the presence of oncogenic
PIK3CA, whereas expression of PLA2G4A—the gene encoding
cPLA2a—remained unchanged (Figure S5C).
Consistent with the predominant role of mTORC2 in driving the
lipid enriched phenotype in PIK3CA MUT cells (Figures 2C and
2D), RICTOR, but not RAPTOR, silencing rescued cPLA2 activity
(Figure 4B), and led to a concomitant reduction in AA and pros-
taglandin E2 (PGE2) levels (Figures 4C and S5D–S5F). Impor-
tantly, mTORC2-specific inhibition was also accompanied by
decreased cPLA2 stability (Figure S5G). To elucidate the mech-
anism underlying this observation, known substrates of
mTORC2 including serum/glucocorticoid-regulated kinase 1
(SGK-1) and the protein kinase C (PKC) isoforms were inhibited
in PIK3CA MUT cells. ASB14780—an indole-based compound
that inhibits both cPLA2 translocation to membrane compart-
ments and the interaction between phospholipid substrates
with the enzyme active site (McKew et al., 2008; Tomoo et al.,
2014)—was used as a positive control. Importantly, a significant
reduction in AA and cPLA2’s enzymatic activity, reminiscent of
that observed upon ASB14780 inhibition, was only observed
following pharmacological and small interfering RNA (siRNA)-
mediated inhibition of PKCz (Figures 4D, 4E, and S5H–S5K).
Previous studies have shown that phosphorylation of cPLA2
on S505 regulates its activity and stability and that this is medi-
ated, at least in part, by the p38 MAPK/ERK signaling pathway
(Kramer et al., 1996; Lin et al., 1993). The contribution of PI3K-(F and G) Immunoblot analysis of the MCF10A PIK3CA isogenic panel following g
factors (F) or PKCz inhibition with 1 mM peptide inhibitor for 72 h (G).
(H) Immunoblot analysis of activated Rac-1 and p38 MAPK in the MCF10A PIK3C
(I) In vitro kinase assay of 100 ng and 0.5 mg/mL purified PKCz and cPLA2 protein
(J) Immunoblot analysis of anti-HA immunoprecipitates derived from HA-tagged
(K) Immunoblot analysis of anti-HA immunoprecipitates derived from HA-tagged c
with 1 mM PKCz peptide inhibitor for 48 h.
(L) AA levels across H1047R MUT cells with CRISPR knockout of PLA2G4A reco
(M) Diagram summarizing the proposed model for PI3K-mTORC2-PKCz and cal
and downstream eicosanoids. Data are presented as the mean ± SEM of n = 3–
periments. n.s., not significant; *p% 0.05; **p% 0.01; ***p% 0.001. p values in (A)
(L) with one-way ANOVA, followed by unpaired, two-tailed Student’s t test with B
1602 Cell 181, 1596–1611, June 25, 2020mTORC2 signaling to this process is unknown, as is the role of
PKCz in the regulation of cPLA2. Consistent with PKCz being a
direct substrate of PDK-1 (Chou et al., 1998) andmTORC2 phos-
phorylation (Li and Gao, 2014), it was found to be hyperphos-
phorylated in PIK3CA MUT cells (Figure 4F) and breast PDX
tumors (Figure S5L). Moreover, its inhibition led to a marked
reduction in MAPK/ERK signaling (Figure 4G), as well as p38
MAPK phosphorylation and active GTP-bound Rac-1 (Fig-
ure 4H), culminating in reduced cPLA2 phosphorylation at the
S505 site (Figures 4G and S5L).
In addition to S505 phosphorylation, an increase in intracel-
lular calcium levels is essential for sustained phospholipase ac-
tivity and liberation of AA by cPLA2 (Ambs et al., 1995; Clark
et al., 1995). Given that elevated PIP3 levels, induced by onco-
genic PIK3CA, promote the activation of phospholipase C
gamma 1 (PLCg1), leading to an increase in cytosolic calcium
via generation of inositol-1,4,5-trisphosphate (IP3) (Rameh
et al., 1998), we hypothesized that this signaling node could
also play a role in regulating cPLA2 activity and AA release down-
stream of active PI3Ka. In line with this premise, we observed
higher phosphorylation of PLCg1 (Figure S6A) and significantly
elevated intracellular calcium levels in PIK3CA MUT cells (Fig-
ure S6B). Although genetic and pharmacological (U73122) inhibi-
tion of PLCg1 led to a significant reduction in calcium flux in both
PIK3CA WT and MUT cells (Figures S6C–S6E), an inhibitory ef-
fect on cPLA2 activity and AA levels was only observed in the
MUT cells (Figures S6F–S6H), highlighting the importance of
PLCg1-mediated Ca2+ flux in sustaining elevated cPLA2 activity
in the context of oncogenic PIK3CA.
Finally, because cPLA2 has a predicted PKCz phosphorylation
site (T376), we tested the possibility that it could serve as a direct
substrate for PKCz. In vitro kinase assays using purified PKCz
and cPLA2 suggested a direct interaction and phosphorylation
(Figure 4I), and this was confirmed following immunoprecipita-
tion (Figure 4J) and proximity ligation activity (PLA) assays (Fig-
ures S6I and S6J). To further evaluate cPLA2 as a candidate sub-
strate for PKCz, we developed a custom antibody recognizing
the cPLA2 T376 phosphorylation site. Specificity was validated
in both serum starved/stimulated samples (Figure S6K, left
panel), following PKCz inhibition (Figures S5K and S6K, middle),
and in cPLA2 CRISPR knockout cells overexpressing a phos-
phoresistant MUT (T376A) cPLA2 (Figure S6K, right panel).
Importantly, increased T376 phosphorylation was observed in
the presence of oncogenic PIK3CA and this was reduced to
levels equivalent to PIK3CA WT cells upon PKCz inhibition
(Figure 4K).rowth factor deprivation for 16 h and 30 min stimulation with serum and growth
A isogenic panel following PKCz inhibition with 1 mM peptide inhibitor for 72 h.
s, respectively.
cPLA2 transfected MCF10A PIK3CA WT and MUT cells.
PLA2 transfectedMCF10A PIK3CAWT andMUT cells treated where indicated
nstituted with WT or phosphoresistant cPLA2 isoforms.
cium-dependent activation of cPLA2, leading to a concomitant increase in AA
6 biological replicates and are representative of at least two independent ex-
were calculated with unpaired, two tailed Student’s t test, and in (B)–(E), (I), and
onferroni correction.
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Figure 5. Genetic and Pharmacological Inhibition of cPLA2 Selectively Reduces Oncogenic PIK3CA-Mediated Tumorigenicity
(A–D) Cell viability of (A) PIK3CAWT and MUT MCF10A cells, and (B) breast cancer cell lines (PIK3CAWT: MDAMB134, Hs578T, AU565; PIK3CAMUT: MCF-7,
CAL-51, MDAMB453) following treatment with increasing concentrations (20 nM–10 mM) of ASB14780 under full serum conditions for 72 h. The same treatments
were also performed under fatty acid-free conditions in (C) and (D), in the presence or absence of exogenous supplementation of 25 mM AA.
(E) Clonogenic assays of MCF10A PIK3CA WT and MUT cells treated with increasing concentrations of ASB14780 as in (A)–(D). Treatments were performed
under fatty acid-free conditions, with or without the supplementation of 25 mM AA.
(F) Immunoblot analysis confirming specific knockdown of cPLA2 using two independent constitutive shRNAs (sh1 and sh5) (left) and reduction in AA levels in
MCF10A E545K/H1047R MUT cells using REIMS.
(G) Proliferation of MCF10A H1047RMUT cells expressing shGFP, cPLA2-sh1, or cPLA2-sh5 under exogenous FAF conditions. Sulforhodamine B (SRB) protein
staining was used to measure cell proliferation over 5 days.
(legend continued on next page)
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phorylation sites (S505 and T376), endogenous cPLA2 in
PIK3CA WT and H1047R MUT cells was reconstituted with WT
or phosphoresistant MUT of cPLA2 (S505A or T376A) (Figure 4L).
Knockout of cPLA2 in H1047R cells reduced AA to levels equiv-
alent to the PIK3CAWT background, and this could be rescued
with ectopic expression of the WT, but not MUT (S505A or
T376A) cPLA2 (Figure 4L). Interestingly, the activity of exoge-
nously expressed WT or MUT cPLA2 largely mirrored the trends
in AA that were previously detected by REIMS (Figure S6L), sug-
gesting that cPLA2 activity is highly dependent on the phosphor-
ylation of S505 and T376 in the context of oncogenic PIK3CA.
Overall, our model provides a unifying framework for several pre-
viously unconnected components of PI3K signaling, which
converge on cPLA2 activation and enhanced AA metabolism
(Figure 4M).
cPLA2 Inhibition and Dietary Fat Restriction Suppress
PIK3CA-Induced Tumorigenicity and Restore Anti-
cancer Immune Responses
If cPLA2 is required for PIK3CA oncogenicity, then targeting this
enzyme could represent an attractive therapeutic strategy. For
this, we used the inhibitor ASB14780, which displays excellent
oral bioavailability and higher specificity for the cPLA2 isoform
than other commonly used compounds such as Efipladib and
Ecopladib (Lee et al., 2007; Tomoo et al., 2014). Furthermore,
ASB14780 has been shown to ameliorate inflammatory pathol-
ogies including non-alcoholic fatty liver disease (NAFLD) and
chronic obstructive pulmonary disease (COPD) through sup-
pression of AA and prostaglandin synthesis (Kanai et al., 2016;
Tomoo et al., 2014). However, the potential anti-neoplastic prop-
erties of this inhibitor remain obscure. Of note, PIK3CAmutation
sensitized cells to pharmacological inhibition of cPLA2 with
ASB14780 (Figures 5A and 5B), and this effect was more prom-
inent under exogenous FA-free conditions (Figures 5C and 5D),
alleviating any compensatory mechanisms to obtain AA. In addi-
tion to viability, cPLA2 inhibition significantly reduced the clono-
genicity of PIK3CA MUT cells, and, importantly, both could be
rescued by exogenous supplementation of AA (Figures 5C, 5D,
and 5E). Near-identical results were obtained following genetic
knockdown of cPLA2 using two constitutive short-hairpin
RNAs (shRNAs, denoted as cPLA2-sh1 and cPLA2-sh5) (Figures
5F, 5G, and S6M), while WT cells were unaffected, suggesting
that cPLA2 is dispensable in this setting (Figure S6N). To further
confirm the importance of cPLA2-induced AA metabolism in
PIK3CA MUT cancers, we suppressed cPLA2 in the isogenic
panel and assessed their ability to form colonies under FA-free
conditions. Although no significant difference in colony forma-
tion was detected in PIK3CA WT cells, there was a marked
reduction in the number of colonies following cPLA2 knockdown
in the MUT cells that was restored in the presence of AA
(Figure 5H). Furthermore, using an inducible shRNA against(H) Clonogenic assays of MCF10A PIK3CAWT andMUT cells expressing shGFP,
25 mMAA. Data in (A)–(H) are presented as the mean ± SEM of n = 3–4 biological r
in (D) are presented as themean viability of three PIK3CAMUT (MCF-7, CAL-51, M
n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001; p values in (A)–(D) and (G) we
way ANOVA followed by unpaired, two-tailed Student’s t test with Bonferroni co
1604 Cell 181, 1596–1611, June 25, 2020cPLA2, we demonstrated that PIK3CA MUT, but not WT cells,
rely on cPLA2 to form epithelial acini in 3D culture and sustain
their proliferation (Figures 6A–6C).
To further evaluate the therapeutic effect of cPLA2 inhibition in
primary breast cancers, we treated triple negative breast cancer
(TNBC) (Figure 6D) PIK3CA WT (Figure 6E) and MUT (Figure 6F)
PDX-bearing mice with the ASB14780 inhibitor in conjunction
with a normal or near-isocaloric fat-free diet. A significant reduc-
tion in tumor weight was only observed in the PIK3CAMUT PDX
model when both the inhibitor and a fat-free diet were adminis-
tered in combination (Figure 6F). Corroborating these observa-
tions, histological analysis did not reveal any changes in tumor
area for the PIK3CAWT BR1458 model (Figures 6G, left panels,
and 6H), while a striking reduction in viable tumor regions was
observed in PIK3CA MUT PDX-bearing mice treated with
ASB14780 in fat-free diet (Figures 6G, right panels, and 6I).
The concomitant increase in necrotic regions (as indicated by
areas of pale eosinophilic cytoplasms, in addition to loss of
nuclei and karyolysis), evidently contributed to a substantial pro-
portion of the overall weight of the PIK3CA MUT-bearing tumor
that was left after treatment of ASB14780 in fat-free diet (Fig-
ure 6G, bottom right panel). In the interest of measuring AA levels
at the end of the treatment regime (Figure 6D), resected tumors
were analyzed directly with REIMS. Although a fat-free diet alone
led to a modest, yet significant reduction in the AA levels of the
PDX tumors, the decrease was significantly more pronounced
when accompanied with cPLA2 inhibition (Figures 6J and 6K),
highlighting the role of dietary AA restriction in therapy response
(Figures 6E–6I).
The observation that cPLA2 inhibition and fat-free diet selec-
tively reduces the tumorigenicity of PIK3CA MUT cells raises
the interesting prospect of modulating this response by altering
dietary fat content. Indeed, it is becoming increasingly appreci-
ated that the diet of Western populations commonly contains
an excess of pro-inflammatory omega-6 to omega-3 FAs by up
to 50 times (popularly referred to as the ‘‘Western’’ diet), and
this may be implicated in the progression of breast and colo-
rectal cancers (Patterson et al., 2012; Simopoulos, 2008). To
further explore this premise, we injected triple negative CAL51
(PIK3CA MUT) and Hs578T (PIK3CA WT) cell lines stably ex-
pressing either control shGFP, or two independent shRNAs tar-
geting cPLA2 (cPLA2-sh1 or sh5) into the mammary fat pad of
BALB/c nude mice that had been preconditioned on either fat-
free, balanced (omega6:omega3 = 1:1) or ‘‘Western’’ (omega6:o-
mega3 = 50:1) diets (Figure 7A). Consistent with pharmacolog-
ical inhibition, knockdown of cPLA2 significantly impaired the
growth ofPIK3CAMUT tumor xenografts under fat-free diet con-
ditions (Figure 7B), and this therapeutic effect was completely
reversed when animals were fed the AA-enriched ‘‘Western’’
diet (Figures 7C and 7D). Although there was a trend toward a
reduction in overall tumor weights under a balanced diet, this
did not reach statistical significance (Figures S7A and S7B). IncPLA2-sh1, or cPLA2-sh5 under FAF conditions, supplemented with or without
eplicates and are representative of at least two independent experiments. Data
DAMB453) andWT (MDAMB134, Hs578T, AU565) measured in triplicate wells.
re calculated using two-way ANOVA. For (E, right), (F, right), and (H, right), one-
rrection was applied.
A B C
D
E F G
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(legend on next page)
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by these treatments (Figures 7E–7G, S7C, and S7D). Further
corroborating our findings, genetic inhibition of cPLA2 only
reduced viable tumor area in animals with PIK3CA MUT tumors
when those were fed a fat-free diet, while no anti-neoplastic
benefit was conferred under a ‘‘Western’’ diet (Figures 7H–7J).
REIMS profiling of excised tumors revealed that AA levels
were significantly altered in concordance with targeting cPLA2
and dietary fat intake (Figures 7K and S7E). Interestingly, a
more substantial AA reduction was observed in PIK3CA MUT
xenograft tumors following cPLA2-knockdown and administra-
tion of fat-free diet (40%–50%decrease), as compared toWT tu-
mors (20% decrease) (Figures 7K and 7L, S7E, and S7F). In line
with our previous in vivo study (Figure 6), these findings demon-
strate that themodulation of dietary fat content, and supplemen-
tation of omega-6 FAs either in a balanced ratio with omega-3
FAs, or to a much larger extent in the ‘‘Western’’ diet, completely
abolishes the therapeutic benefit of cPLA2 inhibition in PIK3CA
MUT tumors.
In addition to promoting growth and proliferation through both
autocrine andparacrinemechanisms, AAand its downstreamme-
tabolites have also been implicated in themetabolic remodeling of
the tumor microenvironment. One of their major consequences is
inhibition of the anti-cancer immune responses, ultimately leading
to immune evasion and tumor progression (Bo¨ttcher et al., 2018;
Zelenay et al., 2015). Although the BALB/c nude mice used in
this study lack adaptive immunity in the form of T cells, these an-
imals mount robust innate immune responses predominantly
mediated by natural killer (NK) cells (Lee et al., 2015; Okada
et al., 2019). We therefore sought to investigate how the various
therapeutic and dietary regimes that were used in this study
impact NK cell responses. To do this, the levels of type I inter-
feron-induced chemokines (CCL5 and CX3CL1) and expression
of a major NK cell-activating receptor (NKp46) were measured
in tumors from different treatment groups.
Coinciding with the largest reduction in AA levels (Figure 6K), a
marked increase in CCL5 and CX3CL1 was only observed in the
BR1282 (PIK3CA MUT) PDX tumor following co-administration
of ASB14780 and fat-free diet (Figures S7G and S7I). Similar re-
sults were obtained in the CAL51 (PIK3CA MUT)-derived xeno-
graft tumor model, where the increase in chemokine levels was
rescued when mice were fed the AA-enriched ‘‘Western’’ diet
(Figures S7H and S7J).Figure 6. Oncogenic PIK3CA Serves as a Defining Biomarker for Sens
(A) Immunoblot analysis confirming inducible knockdown of cPLA2 following ind
(B) 3D acini formation of MCF10A PIK3CAWT and MUT cells following doxycyclin
Alexa Fluor 546), F-actin (red, Phalloidin 633), and DAPI (blue).
(C) Quantification of Ki-67 staining from treatments in (B).
(D) Schematic of in vivo experimental design and tumor profiling with REIMS.
(E and F) Tumor weights of (E) PIK3CA WT (BR1458) and (F) C420R MUT (BR128
inhibitor ASB14780 under FAF diet (n = 8 mice for the BR1458 model, and n = 7
(G) Representative images of H&E staining from resected tumors in (E) and (F).
correspond to necrotic tissue.
(H and I) Quantification of viable tumor area from (H) PIK3CAWT (BR1458) and (I
(J and K) AA levels measured by REIMS in (J) PIK3CAWT (BR1458) and (K) MUT (B
(C), (J), and (K) represent mean ± SEM, with data in (J) and (K) corresponding to
**p < 0.01; ***p < 0.001; p values in (E), (F), and (H)–(K) were calculated using one
correction.
1606 Cell 181, 1596–1611, June 25, 2020In agreement with the chemokine analysis, tumor infiltration of
NK cells was significantly increased in PIK3CA MUT tumors by
dietary and therapeutic interventions, with dual inhibition (either
with ASB14780 or shRNA) of cPLA2 and fat-free diet leading to
the largest increase in NKp46 staining (Figures S7K, S7L, S7N,
and S7O). It is also noteworthy that PIK3CA WT PDX and cell
line-derived xenograft tumors contained relatively higher base-
line levels of CCL5, CX3CL5, and NKp46 expression, as
compared to MUT tumors, and these were not significantly
altered by cPLA2 inhibition and/or changes in the diet (Figures
S7G–S7J, S7M, and S7P). Considered together, these data sug-
gest that oncogenic PIK3CA might suppress BC immunoge-
nicity, at least in part, through regulation of AA metabolism,
and this can be reversed through co-administration of cPLA2 in-
hibition and dietary fat restriction.
DISCUSSION
Unraveling the interplay between genotype and metabolic
phenotype, as well as their complex interactions with nutrient
availability, unequivocally plays a major role in understanding
disease pathogenesis and identifying novel therapeutic interven-
tions. Here, we demonstrate that the iKnife/REIMS enables close
to real-time prediction of clinically relevant tumor features based
on their metabolic fingerprints, offering a novel repertoire for
cancer diagnosis and therapy decision-making. Among these,
is oncogenic PIK3CA, which triggers almost ‘‘the perfect storm’’
of signaling events, culminating in the overproduction of AA and
downstream eicosanoids via the activation of cPLA2.
We have evidence of the central role of AA and eicosanoids in
a wide range of disorders including cancer, obesity, diabetes,
asthma, and autoimmune disorders (Dennis and Norris, 2015;
Sonnweber et al., 2018; Wang and Dubois, 2010). However,
the signal transduction pathways behind their activation, as
well as the molecular cues that link these bio-active lipids with
growth factor-independent cell proliferation have remained
largely obscure. Our results demonstrate that mTORC2 down-
stream of oncogenic PIK3CA acts as a pivotal signaling hub for
driving enhanced AA metabolism to sustain cell proliferation
beyond a cell autonomousmanner. This is particularly interesting
in light of evidence obtained from in situ single-cell analysis of
primary breast tumors, showing often that only a small fraction
of cancer cells within a tumor carry PIK3CA mutations, whileitivity of Pre-clinical Models to cPLA2 Inhibition
uction with 2 mg/mL doxycycline.
e-induced cPLA2-sh1 or shGFP expression. Cells were stained for Ki-67 (pink,
2) breast PDX tumors treated with 100 mg/kg of the cPLA2a pharmacological
mice for the BR1282 for both the vehicle- and ASB14780-treated groups).
The black masks in (G) represent viable tumor area, while unshaded regions
) PIK3CA MUT (BR1282) tumor sections based on the analysis depicted in (G).
R1282) tumors excised and snap frozen 2 h after the final dosing. Error bars in
tumor REIMS measurements from n = 7–8 mice. n.s., not significant;*p < 0.05;
-way ANOVA followed by unpaired, two-tailed Student’s t test with Bonferroni
AB C D
E F G
H I J
K L
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zewska et al., 2015). Given that AA has been shown to induce
both PI3K (Hughes-Fulford et al., 2006) and MAPK (Alexander
et al., 2006) signaling, PIK3CA MUT cells could trigger a snow-
ball effect, through overproduction of AA, affecting not only their
own signaling and proliferation, but also that of their adjacent
PIK3CAWT cells. Moreover, in light of the role of prostaglandins
in lymphangiogenesis (Lala et al., 2018), the paracrine effects of
AA could be of further relevance to the activity of PI3Ka in endo-
thelial cells (Okkenhaug et al., 2016; Wang and Dubois, 2010).
Eicosanoids no longer represent the missing link between
inflammation and cancer (Greene et al., 2011). Elevated tumor-
derived PGE2 contributes to immune evasion by preventing the
interferon gamma (IFNg)-dependent upregulation of ICAM-1
that is pertinent for complete CD8(+) T cells activation (Basingab
et al., 2016). In addition, autocrine PGE2 impairs NK cell viability
and chemokine production and leads to downregulation of the
chemokine receptors of cDC1 that promote their recruitment
into tumors (Bo¨ttcher et al., 2018). Importantly, there is a strong
positive correlation between the gene signature of cDC1 and
NK cells and better overall survival in melanoma and breast can-
cers (Bo¨ttcher et al., 2018), suggesting that monitoring the immu-
nomodulatory functions of prostaglandins via PI3K/Akt pathway
inhibition could have important clinical implications. Indeed, we
have shown that modulation of AA levels in PIK3CAMUT tumors
through cPLA2 inhibition in combinationwith dietary fat restriction
increases intra-tumor infiltration of NK cells and their associated
chemokines, while this can be reversed by the ‘‘Western’’ diet,
which contains an excess of omega6-FAs. NK cell markers
were largely unaffected in PIK3CA WT tumors, and this could
reflect their lower intra-tumor AA levels that are likely attributable
to reduced cPLA2 activity and FA uptake, as compared to
PIK3CAMUT cells. In light of recent evidence showing that block-
ing PI3K signaling with the pan-PI3K inhibitor BKM120 increases
tumor-immune infiltrate and rendersPIK3CAMUTmouse bladder
tumors more susceptible to PD-1 blockade (Borcoman et al.,
2019), our model raises important considerations for how immu-
notherapies may be successfully applied to oncogenic PIK3CA
MUT tumors that may be inherently less immunogenic, at least
in part, due to enhanced AA production.
Another way to relieve the immunosuppressive effects of tu-
mor cells is by inhibiting COX activity via the use of non-steroidal
anti-inflammatory drugs (NSAIDs), such as aspirin. Notably,Figure 7. Dietary Supplementation of Arachidonic Acid Reverses the S
(A) Schematic of in vivo experimental design and profiling of breast cancer cell li
(B and C) Relative tumor growth of CAL-51 (PIK3CA MUT)-derived xenografts s
(cPLA2-sh1 and cPLA2-sh5) under (B) fat-free or (C) ‘‘Western’’ diets.
(D) Weights of tumors excised at the end of the experiments (B) and (C).
(E and F) Relative tumor growth of Hs578T (PIK3CAWT)-derived xenografts stably
(E) fat-free or (F) ‘‘Western’’ diets.
(G) Weights of tumors excised at the end of the experiments (E) and (F).
(H) Representative images of H&E staining from resected tumors in (D) and (G).
correspond to necrotic tissue.
(I and J) Quantification of viable tumor area from (I) PIK3CA MUT (CAL-51) and (
(K and L) AA levels measured by REIMS in (K) PIK3CA MUT (CAL-51) and (L) PIK
scaled values to the appropriate shGFP-fat-free diet condition. Data in (B), (C), (E
REIMS measurements from n = 3–5 mice. n.s., not significant; *p < 0.05; **p < 0.0
ANOVA, and one-way ANOVA followed by unpaired, two-tailed Student’s t test w
1608 Cell 181, 1596–1611, June 25, 2020oncogenic PIK3CA has been shown to sensitize cancer cells to
aspirin (Henry et al., 2017; Liao et al., 2012) and, based on our
findings, it is tempting to speculate that this connection could
be true, in part because of the heightened capacity of PIK3CA
MUT cells for high AA production. However, further studies are
needed to ascertain this connection, because evidence sug-
gests that the growth inhibitory effect of aspirin in PIK3CA
MUT cells is likely to be COX-2-independent (Henry et al., 2017).
Although PI3K pathway inhibitors have shown some efficacy in
treating advanced solid tumors, the majority has been associ-
ated with only partial tumor remission and they are often accom-
panied by severe side effects (Fruman et al., 2017; Li et al., 2018).
Recent evidence suggests that oneway to enhance their efficacy
is by suppressing their insulin feedback through adoption of a
ketogenic diet (Hopkins et al., 2018). Indeed, diet could play a
much more significant role in therapy response than previously
anticipated. Our data suggest that a diet rich in FAs limits the ef-
ficacy of the cPLA2 inhibitor, as PIK3CA MUT tumors likely
depend on their high flux of extracellular FA intake to compen-
sate for the loss of AA. This observation raises the possibility
that adopting a diet withoutmeat and dairy products (major sour-
ces of AA) could dramatically improve the sensitivity of the
cPLA2 inhibitor and help restore tumor immunogenicity, sug-
gesting a novel path for future clinical trials where nutrition will
play a major role in disease management and treatment.STAR+METHODS
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Rabbit polyclonal anti-phospho-p38 MAPK
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Rabbit monoclonal anti-HA-Tag Cell Signaling Technology Cat# 3724; RRID: AB_1549585
Rabbit monoclonal anti-GAPDH Cell Signaling Technology Cat# 2118; RRID: AB_561053
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Rabbit polyclonal anti-PKCzeta Abcam Cat# ab59364; RRID: AB_944858
Rabbit monoclonal anti-phospho-PKCzeta
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Abcam Cat# ab62372; RRID: AB_946309
Rabbit polyclonal anti-PKCepsilon Abcam Cat# ab63638; RRID: AB_1142276
Rabbit polyclonal anti-phospho-
PKCepsilon (Ser729)
Abcam Cat# ab63387; RRID: AB_1142277
Rabbit monoclonal anti-secretory
phospholipase A2
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Mouse monoclonal anti-PKCbeta II (F-7) Santa Cruz Biotechnology Cat# sc-13149; RRID: AB_628144
Mouse monoclonal anti-PKCzeta (B-7) Santa Cruz Biotechnology Cat# sc-393218
Mouse monoclonal anti-phospho-RKIP
(Ser153)
Santa Cruz Biotechnology Cat# sc-135779; RRID: AB_2163163
Normal rabbit IgG Santa Cruz Biotechnology Cat# sc-2027; RRID: AB_737197
Mouse monoclonal anti-phospho-Rb
(Thr821/826)
Santa Cruz Biotechnology Cat# sc-271930; RRID: AB_670923
Rabbit polyclonal anti-phospholipase
A2 (iPLA2)
Sigma-Aldrich Cat# SAB4200129; RRID: AB_11129638
Rabbit monoclonal anti-phospho-PKCzeta
(Thr410)
Thermo Fisher Scientific Cat# MA5-15060; RRID: AB_10983263
Mouse monoclonal anti-SREBP1 BD Biosciences Cat#557036; RRID: AB_396559
Goat anti-rabbit IgG (H+L)-HRP conjugate Bio-Rad Cat#170-6515; RRID: AB_11125142
Goat anti-mouse IgG (H+L)-HRP conjugate Bio-Rad Cat#170-6516; RRID: AB_11125547
Mouse polyclonal anti-Nkp46/ncr1 R and D systems Cat#AF2225; RRID: AB_355192
Rabbit monoclonal anti-Ki-67 (D3B5) Cell Signaling Technology Cat# 9129; RRID: AB_2687446
Goat anti-Mouse IgG (H+L) secondary
antibody, Alexa Fluor 546
Thermo Fisher Scientific Cat# A-11003; RRID: AB_2534071
Phalloidin-iFluor 633 Abcam Cat# ab176758
Rabbit polyclonal anti-phospho-cPLA2
(Thr376) (Peptide name: PLA2G4A-
369:383-pT376)
This paper (produced by Thermo Fisher
Scientific)
Cat# UE1820P-T-AB1792
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Bacterial and Virus Strains
MAX Efficiency DH5a Competent Cells Thermo Fisher Scientific Cat#18258012
Biological Samples
Primary human breast tissue Imperial College Tissue Bank Cat# IKB180
Primary human breast tissue Imperial College Tissue Bank Cat# IKB83
Primary human breast tissue Imperial College Tissue Bank Cat# IKB092
Primary human breast tissue Imperial College Tissue Bank Cat# IKB519
Primary human breast tissue Imperial College Tissue Bank Cat# IKB512
Primary human breast tissue Imperial College Tissue Bank Cat# IKB367
Primary human breast tissue Imperial College Tissue Bank Cat# IKB541
Primary human breast tissue Imperial College Tissue Bank Cat# IKB383
Primary human breast tissue Imperial College Tissue Bank Cat# IKB323
Primary human breast tissue Imperial College Tissue Bank Cat# IKB210
Primary human breast tissue Imperial College Tissue Bank Cat# IKB334
Primary human breast tissue Imperial College Tissue Bank Cat# IKB283
Breast PDX model CrownBioscience Cat# BR6695
Breast PDX model CrownBioscience Cat# BR5020
Breast PDX model CrownBioscience Cat# BR5009
Breast PDX model CrownBioscience Cat# BR5022
Breast PDX model CrownBioscience Cat# BR1282
Breast PDX model CrownBioscience Cat# BR5011
Breast PDX model CrownBioscience Cat# BR5014
Breast PDX model CrownBioscience Cat# BR5012
Breast PDX model CrownBioscience Cat# BR5017
Breast PDX model CrownBioscience Cat# BR5013
Breast PDX model CrownBioscience Cat# BR1474
Breast PDX model CrownBioscience Cat# BR3267
Breast PDX model CrownBioscience Cat# BR5010
Breast PDX model CrownBioscience Cat# BR5015
Breast PDX model CrownBioscience Cat# BR5337
Breast PDX model CrownBioscience Cat# BR1115
Breast PDX model CrownBioscience Cat# BR1283
Breast PDX model CrownBioscience Cat# BR1458
Breast PDX model Champions Oncology Cat# CTG1059
Breast PDX model Champions Oncology Cat# CTG1350
Breast PDX model Champions Oncology Cat# CTG1941
Breast PDX model Champions Oncology Cat# CTG2308
Breast PDX model Champions Oncology Cat# CTG0033
Breast PDX model Champions Oncology Cat# CTG0012
Breast PDX model Champions Oncology Cat# CTG0017
Breast PDX model Champions Oncology Cat# CTG0018
Breast PDX model Champions Oncology Cat# CTG0437
Breast PDX model Champions Oncology Cat# CTG0473
Ovarian PDX model Champions Oncology Cat# CTG0253
Ovarian PDX model Champions Oncology Cat# CTG1423
Ovarian PDX model Champions Oncology Cat# CTG1602
Ovarian PDX model Champions Oncology Cat# CTG1627
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Ovarian PDX model Champions Oncology Cat# CTG0252
Ovarian PDX model Champions Oncology Cat# CTG0258
Ovarian PDX model Champions Oncology Cat# CTG0259
Ovarian PDX model Champions Oncology Cat# CTG0486
Pancreatic PDX model Champions Oncology Cat# CTG0292
Pancreatic PDX model Champions Oncology Cat# CTG0381
Pancreatic PDX model Champions Oncology Cat# CTG0391
Pancreatic PDX model Champions Oncology Cat# CTG1485
Pancreatic PDX model Champions Oncology Cat# CTG2205
Pancreatic PDX model Champions Oncology Cat# CTG0282
Pancreatic PDX model Champions Oncology Cat# CTG0283
Pancreatic PDX model Champions Oncology Cat# CTG0284
Pancreatic PDX model Champions Oncology Cat# CTG0285
Pancreatic PDX model Champions Oncology Cat# CTG0286
Sarcoma PDX model Champions Oncology Cat# CTG0886
Sarcoma PDX model Champions Oncology Cat# CTG1084
Sarcoma PDX model Champions Oncology Cat# CTG1116
Sarcoma PDX model Champions Oncology Cat# CTG1255
Sarcoma PDX model Champions Oncology Cat# CTG1628
Sarcoma PDX model Champions Oncology Cat# CTG0142
Sarcoma PDX model Champions Oncology Cat# CTG0143
Sarcoma PDX model Champions Oncology Cat# CTG0241
Sarcoma PDX model Champions Oncology Cat# CTG0242
Sarcoma PDX model Champions Oncology Cat# CTG0243
Colorectal PDX model Champions Oncology Cat# CTG0083
Colorectal PDX model Champions Oncology Cat# CTG0129
Colorectal PDX model Champions Oncology Cat# CTG0360
Colorectal PDX model Champions Oncology Cat# CTG0706
Colorectal PDX model Champions Oncology Cat# CTG0799
Colorectal PDX model Champions Oncology Cat# CTG0058
Colorectal PDX model Champions Oncology Cat# CTG0062
Colorectal PDX model Champions Oncology Cat# CTG0063
Colorectal PDX model Champions Oncology Cat# CTG0065
Colorectal PDX model Champions Oncology Cat# CTG0066
Chemicals, Peptides, and Recombinant Proteins
Hydrocortisone Sigma-Aldrich Cat# H-0888
Insulin-transferrin-selenium GIBCO Cat# 41400-045
Epidermal growth factor (EGF) Peprotech Cat# AF-100-15
Cholera toxin Sigma-Aldrich Cat# C-8052
Insulin Sigma-Aldrich Cat# I-1882
Fatty acid free bovine serum albumin Sigma-Aldrich Cat# A8806
PKC zeta pseudosubstrate inhibitory
peptide
Sigma-Aldrich Cat# P1614
PKC beta II peptide inhibitor Sigma-Aldrich Cat# P-0102
FIPI hydrochloride hydrate Sigma-Aldrich Cat# F5808
4-hydroxytamoxifen Sigma-Aldrich Cat# T176
Bromoenol lactone Sigma-Aldrich Cat# B1552
Cycloheximide Sigma-Aldrich Cat# C7698
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Doxycycline hyclate Sigma-Aldrich Cat# D9891
Arachidonic acid Sigma-Aldrich Cat# 10931
Palmitoleate Sigma-Aldrich Cat# P9417
Palmitate Sigma-Aldrich Cat# P0500
PKC alpha (C2-4) inhibitor peptide Santa Cruz Biotechnology Cat# sc-304
PKC epsilon inhibitor peptide Cambridge Bioscience Cat# CAY17476
Rapamycin Selleckchem Cat# S1039
Torin 1 Selleckchem Cat#S2827
BYL719 Selleckchem Cat# S2814
BKM120 Selleckchem Cat# 2247
MK2206 Selleckchem Cat# S1078
GSK690693 Selleckchem Cat# S1113
GSK650394 Tocris Bioscience Cat# 3572
U73122 Tocris Bioscience Cat# 1268
ASB14780 Axon Medchem Cat# 2578
DharmaFECT-1 transfection reagent Dharmacon Cat# T-2001-02
FuGENE HD Transfection reagent Promega Cat# E2311
Lipid Removal Adsorbent Supelco Cat# 13358
Matrigel Corning Cat# 354230
Paraformaldehyde Sigma-Aldrich Cat# 158127
Triton X-100 Sigma-Aldrich Cat# X100
DAPI (4’,6-Diamidino-2-Phenylindole,
Dihydrochloride)
Thermo Fisher Scientific Cat# D1306
RIPA buffer Thermo Fisher Scientific Cat# 89900
Leupeptin Sigma-Aldrich Cat# L2884
Pepstatin Sigma-Aldrich Cat# P5318
Na3VO4 Sigma-Aldrich Cat# 450243
DL-Dithiothreitol Sigma-Aldrich Cat# 646653
Calyculin A Cell Signaling Technology Cat# 9902
Beta-glycerophosphate Sigma-Aldrich Cat# G9422
PMSF protease inhibitor Cell Signaling Technology Cat# 8553
Bradford reagent Bio-Rad Cat# 5000006
ALLN protease inhibitor Merck-Millipore Cat# 208719
2x Laemmli sample buffer Bio-Rad Cat# 161-0737
4x Laemmli sample buffer Bio-Rad Cat# 161-0747
10X Cell lysis buffer Cell Signaling Technology Cat# 9803
Recombinant human protein kinase C zeta Insight Biotechnology Cat# TP302472
Recombinant human phospholipase A2,
group IVA
Insight Biotechnology Cat# TP320972
Magnesium chloride Sigma-Aldrich Cat# M8266
Bovine serum albumin Sigma-Aldrich Cat# A2153
Puromycin Invivogen Cat# ant-pr-1
Blasticidin Invivogen Cat# ant-bl-1
Critical Commercial Assays
QuikChange Lightning Site-Directed
Mutagenesis Kit
Agilent Cat# 210518
CellTiter96 Aqueous Non-radioactive (MTS)
cell proliferation assay
Promega Cat# G5430
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Fatty Acid Uptake Kit Sigma-Aldrich Cat# MAK156
Cytosolic Phospholipase A2 Assay Kit Abcam Cat# ab133090
Secretory Phospholipase A2 Assay Kit Abcam Cat# ab133089
Diacylglycerol (DAG) Assay Kit Cell Biolabs Inc Cat# MET-5028
Active Rac1 Detection Kit Cell Signaling Technology Cat# 8815
Duolink In Situ Detection Reagents Red Kit Sigma-Aldrich Cat# DUO92008
Minus and Plus PLA probes Sigma-Aldrich Cat# DUO92004 and DUO92002
Fluo-4 Direct Calcium Assay Kit Thermo Fisher Scientific Cat# F10471
RNeasy Plus Mini Kit QIAGEN Cat# 74134
QuantiTect Reverse Transcription Kit QIAGEN Cat#205311
SYBR Select Master Mix Thermo Fisher Scientific Cat# 4472908
QIAamp DNA mini kit QIAGEN Cat# 51304
PNAClamp PIK3CA Mutation Detection Kit Panagene Cat# PNAC-4001
ADP-Glo Kinase Assay Promega Cat# V6930
Arachidonic Acid ELISA Kit Generon Cat# CEB098Ge
Prostaglandin E2 ELISA Kit Enzo Life Sciences Cat# ADI-900-001
Mouse RANTES (CCL5) ELISA Kit Abcam Cat# ab100739
Mouse Fractalkine (CX3CL1) ELISA Kit Abcam Cat# ab100683
Pierce BCA Protein Assay Kit Thermo Fisher Scientific Cat# 23225
Deposited Data
Custom script for quantification of proximity
ligation assay images
This manuscript Github: https://github.com/adamltyson/
foci2D
Custom script for quantification of acini
images
This manuscript Github: https://github.com/adamltyson/
cell-coloc-3D
Custom script for quantification of
calcium flux
This manuscript Github: https://github.com/adamltyson/
CalciumAnalysis
REIMS data for Figure 1D This manuscript Mendeley Data; https://doi.org/10.17632/
xcgc5kpntm.1
REIMS data for Figure 1E This manuscript Mendeley Data; https://doi.org/10.17632/
xcgc5kpntm.1
REIMS data for Figure 1H This manuscript Mendeley Data; https://doi.org/10.17632/
xcgc5kpntm.1
REIMS data for Figure 3B This manuscript Mendeley Data; https://doi.org/10.17632/
xcgc5kpntm.1
REIMS data for Figure 3D This manuscript Mendeley Data; https://doi.org/10.17632/
xcgc5kpntm.1
Significantly altered phospholipids across
breast cancer cell lines of different receptor,
or triple negative status
This manuscript Table S1
Significantly different fatty acids between
MCF10A PIK3CA wild-type and E545K/
H1047R mutant cells
This manuscript Table S4
Experimental Models: Cell Lines
Human PIK3CA (H1047R/+) MCF10A Horizon Discovery Cat# HD 101-011
Human PIK3CA (E545K/+) MCF10A Horizon Discovery Cat# HD 101-002
AU565 (human breast carcinoma) ATCC Cat# CRL-2351; RRID: CVCL_1074
BT20 (human breast carcinoma) ATCC Cat# HTB-19; RRID: CVCL_0178
BT474 (human breast carcinoma) ATCC Cat# HTB-20; RRID: CVCL_0179
BT549 (human breast carcinoma) ATCC Cat# HTB-122; RRID: CVCL_1092
CAL51 (human breast carcinoma) DSMZ Cat# ACC-302; RRID: CVCL_1110
(Continued on next page)
ll
OPEN ACCESS
Cell 181, 1596–1611.e1–e16, June 25, 2020 e6
Article
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
CAMA1 (human breast carcinoma) ATCC Cat# HTB-21; RRID: CVCL_1115
EFM19 (human breast carcinoma) DSMZ Cat# ACC-231; RRID: CVCL_0253
Hs578T (human breast carcinoma) ATCC Cat# HTB-126; RRID: CVCL_0332
JIMT1 (human breast carcinoma) DSMZ Cat# ACC-589; RRID: CVCL_2077
KPL1 (human breast carcinoma) DSMZ Cat# ACC-317; RRID: CVCL_2094
MCF7 (human breast carcinoma) ATCC Cat# HTB-22; RRID: CVCL_0031
MDAMB134 (human breast carcinoma) ATCC Cat# HTB-23; RRID: CVCL_0617
MDAMB157 (human breast carcinoma) ATCC Cat# HTB-24; RRID: CVCL_0618
MDAMB231 (human breast carcinoma) ATCC Cat# HTB-26; RRID: CVCL_0062
MDAMB361 (human breast carcinoma) ATCC Cat# HTB-27; RRID: CVCL_0620
MDAMB436 (human breast carcinoma) ATCC Cat# HTB-130; RRID: CVCL_0623
MDAMB453 (human breast carcinoma) ATCC Cat# HTB-131; RRID: CVCL_0418
MDAMB468 (human breast carcinoma) ATCC Cat# HTB-132; RRID: CVCL_0419
MFM223 (human breast carcinoma) DSMZ Cat# ACC-422; RRID: CVCL_1408
S68 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL_5585
SKBR3 (human breast carcinoma) ATCC Cat# HTB-30; RRID: CVCL_0033
T47D (human breast carcinoma) ATCC Cat# HTB-133; RRID: CVCL_0553
UACC812 (human breast carcinoma) ATCC Cat# CRL-1897; RRID: CVCL_1781
VP229 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL_2754
BT483 (human breast carcinoma) ATCC Cat# HTB-121; RRID: CVCL_2319
HCC1143 (human breast carcinoma) ATCC Cat# CRL-2321; RRID: CVCL_1245
HCC1395 (human breast carcinoma) ATCC Cat# CRL-2324; RRID: CVCL_1249
HCC1428 (human breast carcinoma) ATCC Cat# CRL-2327; RRID: CVCL_1252
HCC1500 (human breast carcinoma) ATCC Cat# CRL-2329; RRID: CVCL_1254
HCC1569 (human breast carcinoma) ATCC Cat# CRL-2330; RRID: CVCL_1255
HCC1937 (human breast carcinoma) ATCC Cat# CRL-2336; RRID: CVCL_0290
HCC1954 (human breast carcinoma) ATCC Cat# CRL-2338; RRID: CVCL_1259
HCC202 (human breast carcinoma) ATCC Cat# CRL-2316; RRID: CVCL_2062
HCC38 (human breast carcinoma) ATCC Cat# CRL-2314; RRID: CVCL_1267
HCC70 (human breast carcinoma) ATCC Cat# CRL-2315; RRID: CVCL_1270
SUM52 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL_3425
ZR751 (human breast carcinoma) ATCC Cat# CRL-1500; RRID: CVCL_0588
ZR7530 (human breast carcinoma) ATCC Cat# CRL-1504; RRID: CVCL_1661
SUM44 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL-3424
SUM159 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL_5423
SUM149 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL_3422
SUM225 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL_5593
SUM229 (human breast carcinoma) Breast Cancer Now (Institute of Cancer
Research)
RRID: CVCL_5594
HEK293T (human embryonic kidney) ATCC Cat# CRL-3216; RRID: CVCL_0063
Human MCF10A PIK3CA WT CRISPR
control cell line
This manuscript N/A
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Human MCF10A PIK3CA WT cPLA2
CRISPR cell line
This manuscript N/A
Human MCF10A PIK3CA H1047R (+/)
CRISPR control cell line
This manuscript N/A
Human MCF10A PIK3CA H1047R (+/)
cPLA2 CRISPR cell line
This manuscript N/A
Experimental Models: Organisms/Strains
Mouse: BALB/c nude (female, age: 6–
8 weeks)
Beijing Anikeeper Biotech (Beijing, China) N/A
Mouse: BALB/c nude (female, age: 7–
9 weeks)
Envigo N/A
Oligonucleotides
Primers for cPLA2 shRNA amplification
(Forward 50-
GTGGAAAGGACGAAACACCGGT-30,
Reverse 50-
TTTGTCTCGAGGTCGAGAATTC-30
Sigma-Aldrich N/A
Mutagenesis primers to generate cPLA2
S505A (Forward 50-
GCAAAGTCACTCAAAGGAGCCAGTG
GATAAGATGTATTG-30, Reverse 50-
CAATACATCTTATCCACTGGCTCCTTT
GAGTGACTTTGC-30
Sigma-Aldrich N/A
Mutagenesis primers to generate
cPLA2 T376A (Forward 50-TTCTTC
ATACTTCTTAACGACTGCTCCCATAAAAA
ATTTGCTTCCAA-30,
Reverse 50-TTGGAAGCAAATTT
TTTATGGGAGCAGTCGTTAAG
AAGTATGAAGAA-30
Sigma-Aldrich N/A
qPCR primers for human cPLA2 (PLA2G4A)
(Forward 50-
GATGAAACTCTAGGGACAGCAAC-30,
Reverse 50-
CTGGGCATGAGCAAACTTCAA-30
Sigma-Aldrich N/A
qPCR primers for human beta-actin
(Forward 50-
GACCCAGATCATGTTTGAGACC-30,
Reverse 50-
CTTCATGAGGTAGTCAGTCAGG-30)
Sigma-Aldrich N/A
Recombinant DNA
pLKO-Tet-On Vector Wiederschain et al., 2009 Addgene ID: 21915
pCMV3-HA-PLA2G4A Sino Biological Cat# HG13126-NY
RICTOR ON-TARGETplus SMARTPool
human siRNA
Dharmacon Cat# L-016984-00-0005
RAPTOR ON-TARGETplus SMARTPool
human siRNA
Dharmacon Cat# L-004107-00-0005
FRAP1 ON-TARGETplus SMARTPool
human siRNA
Dharmacon Cat# L-003008-00-0005
PLCg1 ON-TARGETplus SMARTPool
human siRNA
Dharmacon Cat# L-003559-00-0005
PRKCZ ON-TARGETplus SMARTPool
human siRNA
Dharmacon Cat# L-003526-00-0005
Non-targeting siRNA control Dharmacon Cat# D-001810-01-05
(Continued on next page)
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TRC Lentiviral eGFP shRNA positive control Dharmacon Cat# RHS4459
TRC Lentiviral Human PLA2G4A shRNA 1 Dharmacon Cat# TRCN0000050263
TRC Lentiviral Human PLAG2G4A shRNA 5 Dharmacon Cat# TRCN0000050267
LentiCRISPR v2 Sanjana et al., 2014 Addgene ID: 52961
PLA2G4A sgRNA CRISPR/Cas9 All-in-One
Lentivector Target 2
Applied Biological Materials Cat# K1659207
pCMV-HA-PLA2G4A-S505A This manuscript N/A
pCMV-HA-PLA2G4A-T376A This manuscript N/A
Inducible pLKO-Tet-On-TRC Lentiviral
Human PLA2G4A shRNA 1
This manuscript N/A
Software and Algorithms
R statistical software (version 3.5.1) The R Project https://www.r-project.org/
ProteoWizard MsConvert software (version
3.0.11781)
Chambers et al., 2012 http://proteowizard.sourceforge.net/
download.html
MALDIquant package Gibb and Strimmer, 2012 https://cran.r-project.org/web/packages/
MALDIquant/index.html
ReactomePA package Yu and He, 2016 https://bioconductor.org/packages/
release/bioc/html/ReactomePA.html
MATLAB (2014a, version 8.3.0.532) Mathworks https://www.mathworks.com/products/
matlab.html
GraphPad Prism (version 8.0.1) GraphPad https://www.graphpad.com/
scientific-software/prism/
Database for Annotation, Visualization and
Integrated Discovery (DAVID, version 6.8)
Huang et al., 2009 https://david.ncifcrf.gov/
TargetLynx software Waters Corporation https://www.waters.com/waters/
home.htm
Image Lab Software (version 5.2.1) Bio-Rad https://www.bio-rad.com/en-uk/product/
image-lab-software?ID=KRE6P5E8Z
ImageJ (version 1.51) NIH https://imagej.nih.gov/ij/download.html
Other
Protein G Sepharose beads Sigma-Aldrich Cat# P3296
Dulbecco’s Modified Eagle’s
Medium (DMEM)
GIBCO Cat# 41965-039
Roswell Park Memorial Institute
(RPMI) 1640
GIBCO Cat# 10220-106
Ham’s F12 media Thermo Fisher Scientific Cat# 11765054
DMEM/F-12 GIBCO Cat# 31330-038
Horse Serum Thermo Fisher Scientific Cat# 16050-122
4–15% Criterion TGX Precast Midi
Protein Gel
Bio-Rad Cat# 5671084
4–15% Mini-PROTEAN TGX Precast
Protein Gel
Bio-Rad Cat# 4561083
Electrosurgical bipolar forceps Erbe Elektromedizin (Germany) N/A
ForceTriad electrosurgical unit Covidien (Ireland) N/A
Thermo Exactive orbitrap instrument Thermo Scientific N/A
Waters HSS T3 UPLC column Waters Corporation Cat# 186005614
Waters Xevo TQ-S triple quadrupole mass
spectrometer
Waters Corporation N/A
Normal diet (for PDX study) Keaoxieli Feed (Beijing, China) Cat# 2152
Fat free diet (for PDX study) Xietong Organism (Beijing, China) Cat# RD17112401
(Continued on next page)
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Western diet (omega-3/omega-6 = 1:50)
(For cell line xenograft study)
Research Diets Cat# D19032707
Balanced diet (omega-3/omega-6 = 1:1)
(For cell line xenograft study)
Research Diets Cat# D19032708
Fat free diet (For xenograft study) Research Diets Cat# D19032705
Precellys Lysing Soft tissue
homogenizing kit
Precellys Cat# P000912-LYSK0
Precellys24 homogenizer Bertin Instruments Cat# P000669-PR240-A
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, George
Poulogiannis (george.poulogiannis@icr.ac.uk).
Materials Availability
All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
Data and Code Availability
The code generated during this study are available at GitHub using the following accessions: https://github.com/adamltyson/
CalciumAnalysis, https://github.com/adamltyson/cell-coloc-3D, and https://github.com/adamltyson/foci2D. These accessions are
also provided in the Key Resources Table. The published article includes all REIMS m/z values and putative annotations for signif-
icantly different lipids between various receptor subtypes andMCF10APIK3CA isogenics in the Supplementary Information in Tables
S1 and S4, respectively. Original/source data of REIMS profiles for Figures 1D, 1E, 1H, 3B, and 3D in the paper corresponding to
breast cancer cell lines and tumors is available through Mendeley Data (https://doi.org/10.17632/xcgc5kpntm.1)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human samples
12 primary breast cancer samples from female patients (> 18 years of age) who consented to utilization of tissue for research were
provided by the Imperial College Healthcare NHS Trust Tissue Bank. Other investigators may have received samples from these
same tissues. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based
at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health. Human samples used in this research project were obtained
with evaluation and approval from theWales Research Ethics Committee Reference 17/WA/0161 (Imperial College Healthcare Tissue
Bank Human Tissue Authority license: 12275; Project number R18024), the East of England – Cambridge East Research Ethics Com-
mittee Reference 14/EE/0024, and the project was registered under the Imperial College Tissue Bank.
Animals
Mouse PDX experiments were performed byCrownBioscience in accordancewith approved Institutional Animal Care andUseCom-
mittee (IACUC) protocols and ethical guidelines, and in strict accordance with the Crown Bioscience Guidelines and Standard Oper-
ating Procedures. Two primary human triple-negative breast cancer PDX corresponding to PIK3CAWT (BR1458) or PIK3CA C420R
MUT (BR1282) tumor fragments (2-3 mm in diameter) were inoculated subcutaneously into the breast pad of 7-9-week-old female
immunodeficient BALB/c nude mice weighing 17-23 g and which had not received previous treatments or procedures. Once tumors
reached a volume of 100-200 mm3, mice were randomized into four groups corresponding to either a normal or fatty acid free (FAF)
diet and administered with vehicle (0.5% hydroxypropyl cellulose in sterile water) or 100 mg/kg cPLA2 inhibitor ASB14780 (2578,
Axon Medchem) daily through oral gavage for 21 days. Animals were housed in a specific pathogen free facility in individually vented
cages and provided with diets and distilled water ad libitum. Room temperature was monitored and maintained at 20-25C with the
light cycle set at 12 hours. All animals were checked daily for signs of ill health, as well as for any effects of tumor growth and
treatments on behavior such as mobility, food and water consumption, and body weight gain/loss. Researchers were not blinded
to treatment groups. Tumors were excised 2 hours after the final dosing and snap frozen in preparation for metabolomics/REIMS
processing and histopathological assessment. The mean tumor area as a percent of the total tissue area was initially assessed by
an independent histopathologist, and subsequently quantified using ImageJ version 1.51. Normal and FAF diets were purchasedCell 181, 1596–1611.e1–e16, June 25, 2020 e10
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All animal work undertaken at the Institute of Cancer Research was carried out under UK Home Office Project Licenses
P6AB1448A (Establishment License, X702B0E74 70/2902) and was approved by the Animal Welfare and Ethical Review Body at
the ICR. For cell line-derived xenograft studies, 7-9 week old female immunodeficient BALB/c nudemice weighing 18-25 g andwhich
had not received previous treatments or procedures were initially pre-conditioned on fat free, balanced (omega3/omega6 1:1) or
Western (omega3/omega6 1:50) diets for 2 weeks to assess tolerability. In order for the animal feed to be controlled, cages were ran-
domized to treatment groups rather than individual mice, and this occurred prior to orthotopic injections. Animals were subsequently
injected with 2.5x106 triple negative CAL51 (PIK3CA mutant) or Hs578T (PIK3CA WT) cells expressing either control shGFP or two
independent shRNAs targeting cPLA2 (cPLA2-sh1 or cPLA2-sh5) in 100 mL PBS:matrigel (50:50) into the right mammary fat pad. An-
imals were housed in a specific pathogen free facility in individually vented cages (no more than 4 mice per cage) and provided with
diets and distilled water ad libitum. Room temperature was monitored and maintained at 20-25Cwith the light cycle set at 12 hours.
All animals were checked daily for signs of ill health, as well as for any effects of tumor growth and treatments on behavior such as
mobility, food and water consumption, and body weight gain/loss. Owing to the nature of the diets, blinding was not possible. Tumor
measurements were taken twice weekly in three dimensions (width, length and depth), and presented as relative tumor growth
normalized to first measurement day. Mice were excluded from the analysis if the primary tumor engrafted subcutaneously or into
the peritoneum instead of the mammary fat pad. On the final day of the experiment, tumors were excised and immediately snap
frozen in preparation for metabolomics/REIMS processing and histopathological assessment. The mean tumor area was quantified
as a percent of the total tissue area using ImageJ version 1.51. Fat free, balanced andWestern diets were purchased from Research
Diets Inc. (D19032705, D19032708, D19032707, respectively). The composition of the diets used for the cell line xenograft study are
summarized in Table S6
Fresh frozen breast patient-derived xenograft (PDX) tumors were obtained from Crown Bioscience, and additional breast, ovarian,
pancreatic, sarcoma and colorectal PDX tumors were kindly provided by Champions Oncology. These are described in the Key Re-
sources Table. The PIK3CA mutational status for all 66 PDX tumor samples is summarized in Table S5.
Cell culture
Human female breast carcinoma cell lines AU565 BT20, BT474, BT549, CAL51, CAMA1, EFM19, Hs578T, JIMT1, KPL1, MCF7,
MDAMB134, MDAMB157, MDAMB231, MDAMB361, MDAMB436, MDAMB453, MDAMB468, MFM223, S68, SKBR3, T47D,
UACC812 and VP229 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (GIBCO, 41965-039) and BT483,
HCC1143, HCC1395, HCC1428, HCC1500, HCC1569, HCC1937, HCC1954, HCC202, HCC38, HCC70, SUM52, ZR751 and
ZR7530 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 media (Sigma-Aldrich, R8758), both supplemented
with 10% fetal bovine serum (FBS) (GIBCO, 10220-106). SUM44 (human, female), SUM159 (human, female), SUM149 (human, fe-
male), SUM225 (human, female) and SUM229 (human, female) were cultured in Ham’s F12 media (Thermo Fisher Scientific,
11765054) supplemented with 5% FBS, 0.5 mg/ml hydrocortisone (Sigma-Aldrich, H-0888) and 0.4% insulin-transferrin-selenium
(GIBCO, 41400-045) and MCF10A (human, female) cells (including the PIK3CA MUT isogenic panel) were cultured in DMEM/F-12
(GIBCO, 31330-038) supplemented with 5% horse serum (Thermo Fisher Scientific, 16050-122), 20 ng/ml epidermal growth factor
(EGF) (Peprotech, AF-100-15), 100 ng/ml cholera toxin (Sigma-Aldrich, C-8052), 0.5 mg/ml hydrocortisone (Sigma-Aldrich, H-0888)
and 10 mg/ml insulin (Sigma-Aldrich, I1882). For cell culture conditions free of exogenous sources of fatty acids, 10% FBS or 5%
horse serum was replaced with 1% fatty acid bovine serum albumin (BSA) (Sigma-Aldrich, A8806). All cell lines were maintained
at 37C, 5% CO2. All cell lines were authenticated by short tandem repeat analysis (Eurofins Scientific) and were tested and
confirmed to be negative for mycoplasma infection.
METHOD DETAILS
Experimental design
Experiments were repeated multiple times across different cell line and tumor models with similar results as indicated in the figure leg-
ends. Key findings from in vivo experiments were reproduced using orthogonal approaches including cell line xenograft models and
genetic inhibitions. Animals were randomized into treatment groups either individually following PDX engraftment and growth to
100-200 mm3, or in cages following diet preconditioning. Throughout the study researchers were not blinded as data analysis required
prior knowledge of the sample annotation. For in vitro and in vivo experiments, sample size was chosen based on preliminary exper-
iments and previous experience with protocols. No completed data were excluded from the analysis performed in this manuscript.
Mass spectrometry analysis
Cell lines were cultured in 10 cm2 plates and harvested in biological triplicate for REIMS analysis when 80%confluent. After replacing
the media one hour prior to harvesting, the plates were washed twice with ice-cold PBS, and immediately flash frozen in liquid nitro-
gen. 1 mL PBS was added to the cells and cell extracts were scraped and collected in eppendorf tubes and centrifuged for 5 min at
5000rpm. Pellets were flash frozen and stored at 80C. For fresh frozen PDX and primary breast tumors, three separate regions
were sectioned for analysis.e11 Cell 181, 1596–1611.e1–e16, June 25, 2020
ll
OPEN ACCESSArticleREIMS analysis was performed with commercially available electrosurgical bipolar forceps (Erbe Elektromedizin, Germany) con-
nected to a ForceTriad electrosurgical unit (Covidien, Ireland) programmed in Macro bipolar setting using 4 W or 30 W power for cell
lines and tumors, respectively. Bipolar forcepswere connected to the inlet capillary of a Thermo Exactive orbitrap instrument (Thermo
Scientific) using PTFE tubing, allowing for the direct suction of aerosol generated from rapid biomass heating to the mass spectrom-
eter (set up is shown in Figure 1A). The mass spectrometer settings used for phospholipid and fatty acid profiling are summarized in
Table S7.
Metabolomics data pre-processing and analysis
Raw mass spectrometric files were converted to mzXML format using the ProteoWizard MSConvert software (Version 3.0.11781)
(Chambers et al., 2012) and imported into RStudio (Version 3.4.4). Data were pre-processed using the MALDIquant package
(Gibb and Strimmer, 2012). Prior to pre-processing, high quality spectra corresponding to the maximum total ion (TIC) count for
each measurement were selected from each individual sample runs. Spectra were normalized using median scaling determined
from the non-zero intensities across the full scan range (m/z 150-2000), and square root transformed. Peaks were aligned using
the locally weighted scatterplot smoothing (LOWESS) function and detected using median absolute deviation (MAD) with a signal
to noise ratio (SNR) equal to 3. Peak matching was subject to a maximum peak shift of 5 ppm. For further analysis, the median in-
tensity of all biological and technical replicates was calculated, such that each sample is represented by a single spectrum. Themass
ranges ofm/z 600-900 andm/z 150-500 were recorded for the detection of phospholipids and fatty acids, respectively.m/z values of
interest which discriminated significantly between experimental conditions were annotated based on previously performed tandem
mass spectrometry (MS/MS) fragmentation analysis and data available from Lipid Maps (https://www.lipidmaps.org). To assess in-
strument reproducibility, the MDAMB468 cells were included in every REIMS run as a quality control. The spectra obtained were
compared among different batches using unsupervised or guided principal component analysis (gPCA) and no significant batch ef-
fect was observed. Classification and feature-selection was performed using leave-one-out or 3-fold cross validation with random
forest as the classifier, applying the ‘caret’ and ‘randomForest’ packages, while unsupervised analysis was performed using hierar-
chical clustering (Euclidean distance, complete linkage), or non-negative matrix factorization (NMF) using the ‘NMF’ package. Pre-
diction of continuous variables such as ESR1 gene expression was performed using random forest regression analysis with the Tree-
Bagger function in MATLAB (2014a, version 8.3.0.532).
Transfections and site directed mutagenesis
Sub-cloning of cPLA2 sh1 into the pLKO-Tet-On inducible vector was done by first amplifying the shRNA sequence of interest with
the following primers: Forward 50-GTGGAAAGGACGAAACACCGGT-30 and Reverse 50-TTTGTCTCGAGGTCGAGAATTC-30, and
subsequently introducing compatible AgeI and EcoRI restriction sites in the shRNA oligonucleotides and pLKO-Tet-On vector
(TET-pLKO puro was a gift from D. Wiederschain, Addgene plasmid 21915). For lentiviral gene knockdown, PLA2G4A or GFP
shRNAswere transfected in 293T cells using FuGENEHD Transfection reagent (Promega, E2311), according to themanufacturer’s
instructions and infected cells were selected in the presence of 1 mg/ml puromycin. For siRNA knockdown, MCF10A PIK3CAWT and
E545K/H1047R MUT cells were transfected with 25 nM ON-TARGETplus SMARTpool human siRNAs targeting RAPTOR, RICTOR,
FRAP1, PLCg1 or PRKCZ using DharmaFECT-1 Transfection Reagent for 48 hours. HA-tagged cPLA2 was transiently overex-
pressed using 9 mg pCMV3-HA-PLA2G4A vector DNA and 18 mL FuGENE HD Transfection reagent, and experiments were per-
formed 48 hours post transfection.
For generating CRISPR knockouts, MCF10A PIK3CAWT andH1047R cells were transfected with PLA2G4A sgRNACRISPR/Cas9
All-in-One Lentivector Target 2 (Applied Biological Materials, K1659207) or control LentiCRISPR v2 (lentiCRISPR v2 was a gift from
Feng Zhang, Addgene plasmid #52961) according to the manufacturer’s instructions. Immunoblotting and DNA sequencing were
used to validate the isolation of PLA2G4A deleted clones.
Phosphoresistant isoforms of cPLA2 were generated using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent,
210518) according to the manufacturer’s instructions. Briefly, 100 ng of pCMV3-HA-PLA2G4A vector DNA was incubated with
125 ng of the appropriate mutagenesis primers:
S505A Forward 50-GCAAAGTCACTCAAAGGAGCCAGTGGATAAGATGTATTG-30, Reverse 50-CAATACATCTTATCCACTGGC
TCCTTTGAGTGACTTTGC-30;
T376A
Forward 50-TTCTTCATACTTCTTAACGACTGCTCCCATAAAAAATTTGCTTCCAA-30 Reverse 50-TTGGAAGCAAATTTTTTATGGG
AGCAGTCGTTAAGAAGTATGAAGAA-30;
PCR cycling parameters were as follows: initial denaturing at 95C for 2 min, followed by 18 cycles of 20 s denaturing (95C), 10 s
annealing (60C) and 4.5 min elongation (68C). A final elongation step occurred for 5min (68C). To assess the effects of these phos-
phomutants on cPLA2 activity or arachidonic acid (AA) levels, cells were transiently transfected with 9 mg pCMV3-HA-PLA2G4A,
pCMV3-HA-PLA2G4A-S505A or pCMV3-HA-PLA2G4A-T376A vector DNA and 18 mL FuGENE HD Transfection reagent, and ex-
periments were performed 48 hours post transfection.Cell 181, 1596–1611.e1–e16, June 25, 2020 e12
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For colony formation assays, single cell suspensions containing 5x102 MCF10A PIK3CA WT or E545K/H1047R MUT cells were
seeded in 6 well plates and allowed to adhere for 18 hours. Wells were subsequently washed twice with PBS and DMEM-F/12 media
containing growth factors and 1% FAF BSA (herein called ‘FAF media’), supplemented either with 0.1% DMSO or 25 mM AA. After
14 days, colonies were stained with crystal violet, and quantified using ImageJ. For 3D spheroid culture, 5x103 cells were seeded in
round bottom, low attachment 96 well plates (Corning, 7007) and incubated for 14 days. Media was replaced every 3 days. For
ASB14780 viability assays, 5x103 PIK3CA WT (MCF10A, MDAMB134, AU565, Hs578T) or PIK3CA MUT (MCF10A E545K/
H1047R, CAL51, MCF7, MDAMB453) were seeded in 96 well plates in full media and allowed to adhere for 18 hours. Wells were
washed twice with PBS, and FAF media containing either 0.1% DMSO, 20 nM-10 mM ASB14780 or the inhibitor supplemented
with 25 mM AA was added. Viability was assessed after 72 hours using the CellTiter 96 Aqueous Non-Radioactive (MTS) cell prolif-
eration assay (Promega, G5430).
To measure cell proliferation, 5x103 MCF10A isogenic cells expressing GFP control or cPLA2 shRNAs (sh1 and sh5) were seeded
in 96 well plates, left to adhere for 18 hours, washed twice with PBS, and incubated with FAF media. Cell number was determined on
Days 0, 1, 3 and 5 using the Sulforhodamine B (SRB) assay.
To assess eicosanoid-mediated autocrine and paracrine effects on cell proliferation, conditioned media were derived from
MCF10A PIK3CAWT or MUT isogenics. Cells were grown to 80% confluency in full media, after which residual media were washed
off twice with PBS, and cells were cultured with FAFmedia for 48 hours. The conditionedmedia were centrifuged at 2000 g for 20min
to remove cell debris and incubated with Lipid Removal Adsorbent (LRA, Supelco, 13358) at 0.4 g of LRA per 10 mLmedia to deplete
secreted lipids. Following overnight incubation with gentle shaking, lipid-deprived media were centrifuged at 2000 g for 20 min and
supernatants were collected. Proliferation was assessed over 5 days using the SRB assay.
To assess fatty acid uptake, 5x104 MCF10A PIK3CA WT or MUT cells were seeded in 100 mL full medium containing 5% horse
serum in a 96-well plate and incubated for 24 hours at 37C, 5% CO2. Cells were washed twice with PBS and serum deprived for
1 hour before adding 100 mL TF2-C12 Fatty Acid Stock Solution (Sigma-Aldrich, MAK156). After incubating the cells for 1 hour at
37C, the fluorescence signal was measured at Ex/Em = 485/515 nm.
Three-dimensional cell culture
For 3D acini formation,MCF10A cells were grown inMatrigel (Corning, 354230) as described previously (Debnath et al., 2003). Briefly,
PIK3CA isogenic MCF10A cells expressing pLKO-Tet-On inducible shRNA against cPLA2 or GFP were induced with 2 mg/ml doxy-
cycline for 48 hours prior to seeding. A single cell suspension (3x103 cells per well) was plated in assay medium containing 1% FAF
BSA onto eight-well chamber slides coated with a layer of pure growth factor–reduced Matrigel. Cells were then overlaid with a
300 mL of assay medium containing 2% Matrigel and cultured for 10 days. Growth media was replaced every 3 days.
Confocal microscopy
For immunofluorescence, cells were fixed with 4% PFA at room temperature, permeabilized with pre-chilled 0.5% Triton X-100 for
10 min prior to blocking with 2% BSA/PBS for 1 hour. After blocking, cells were incubated overnight at 4C with primary Ki-67 anti-
body (Cell Signaling Technology, 9129) in a humidified chamber. The following day cells were incubated with fluorescently labeled
secondary antibodies Alexa Fluor 546-conjugated secondary antibody (Thermo Fischer Scientific, A-11003) and Phalloidin 633
(Abcam, ab176758) to visualize Ki-67 and F-actin, respectively, 1% BSA/PBS for 1 hour. Slides were mounted using Prolong
Gold anti-fade reagent with DAPI (Invitrogen, D1306). Images were captured using a Zeiss AxioObserver microscope equipped
with a YokogawaCSU-W1 spinning disk unit (Intelligent Imaging Innovations) and a 40x oil objective. Serial z stacks of the acini struc-
tures were acquired at 5 um intervals (usually 10-15 sections per field), and then analyzed with a customMATLAB script (2017b, The
Mathworks Inc.). Images were resampled to isotropic resolution and each spheroid was manually segmented. The DAPI signal was
thresholded using Otsu’s method (Otsu, 1979) following intensity depth correction and smoothing. Holes were then filled and small,
non-cellular objects were removed. The resulting binary nuclei image was used as a mask to measure cellular proliferation.
Enzymatic assays
cPLA2, iPLA2 and sPLA2 activities were measured using commercially available assays (Abcam, ab133089 or ab133090) according
to the manufacturers instructions. Briefly, total cell lysates were obtained using 1x Cell Lysis Buffer (Cell Signaling Technology, 9803)
under non-denaturing conditions. For cPLA2 activity, 10 mL lysate, 5 mL Assay buffer and 200 mL substrate solution containing arach-
idonoyl Thio-PC were incubated at room temperature for one hour. For iPLA2 activity, cell lysates were either untreated (measuring
both cPLA2 and iPLA2 activity) or treated with 5 mM of the iPLA2 specific inhibitor bromoenol lactone (BEL), and activity was deter-
mined as follows: iPLA2 activity = (Activity without BEL) – (Activity with BEL). For sPLA2 activity, conditioned media was obtained
from MCF10A PIK3CA WT and MUT cells and concentrated using a centrifugal vacuum evaporator (‘‘SpeedVac’’). Dried samples
were resuspended in 100 mL Assay Buffer, and 10 mL of this was used for the assay. Cellular diacylglycerol (DAG) levels were
measured using a DAG assay kit according to the manufacturer’s instructions (Cell Biolabs Inc., MET-5028). Briefly, 1x107 cells
were harvested by scraping with 1 mL cold PBS, and pellets were obtained after centrifugation at 1500 g for 10 min. Lipids were
extracted following sonication and incubation with methanol, sodium chloride and chloroform. The lower chloroform phase wase13 Cell 181, 1596–1611.e1–e16, June 25, 2020
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suspend the dried sample, 20 mL of which was used for the assay.
Immunoblot analysis
Cells were washed with ice-cold PBS and lysed on ice for 30 min with cell lysis buffer containing RIPA buffer (Thermo Scientific,
89900) supplemented with 4 mg each of leupeptin (Sigma-Aldrich, L2884) and pepstatin (Sigma-Aldrich, P5318), 2 mM Na3VO4
(Sigma-Aldrich, 450243), 1 mM DL-Dithiothreitol (Sigma-Aldrich, 646653), 10 mM Calyculin A (Cell Signaling Technology, 9902),
250 mM b-glycerophosphate (Sigma-Aldrich, G9422) and 400 mMPMSF protease inhibitor (Cell Signaling Technology, 8553). Lysates
were subjected to centrifugation at 12,000 g for 30min at 4C, and protein concentrations were determined using the Bradford assay
(Bio-Rad, 5000006). Nuclear isolation for mature SREBP probing was performed using a Nuclear Extract Kit (ActiveMotif, 40010) with
10 mg/ml of the protease inhibitor ALLN (Millipore, 208719). Protein lysates were boiled for 10 min and subjected to SDS-PAGE elec-
trophoresis using 4%–15%precast gels (Bio-Rad, 567-1084). Densitometry was calculated using the Image Lab Software 5.2.1 (Bio-
Rad). Affinity purified custom antibodies for phosphorylated cPLA2 on Thr376 were developed by Thermo Fisher Scientific using the
PLA2G4A-369:383 peptide antigen and used at a dilution of 1:500 in 5%BSA/TBST. All other primary antibodies were used at a dilu-
tion of 1:1000 in 5% BSA/TBST solution, and secondary antibodies at 1:5000 in 5% milk/TBST.
Immunoprecipitation analysis
MCF10A PIK3CAWT and MUT isogenics were transiently transfected with HA-tagged cPLA2 (pCMV3-HA-PLA2G4A, Sino Biological,
HG13126-NY) and lysedwith 1XCell Lysis Buffer (Cell Signaling Technologies, 9803) 48 hours post transfection. Equal volumeof diluted
cell lysates containing 4 mg of soluble protein were incubated with 2 mg rabbit anti-HA (Cell Signaling Technology, 3724) or 2 mg normal
rabbit IgG (Santa-Cruz Biotechnology, sc-2027) as a negative control, and were pre-coupled with protein G Sepharose beads (Sigma-
Aldrich, P3296) following incubation at 4C for 4 hours rotating. 1X Cell Lysis Buffer was used to wash the beads four times, after which
samples were resuspended in 30 mL 2x Laemmli sample buffer (Bio-Rad, 161-0737) and boiled for 10 min to release bound proteins.
To detect GTP-bound Rac1, the Active Rac1 Detection Kit (Cell Signaling Technology, 8815) was used, following the manufac-
turer’s instructions. Briefly, cell lysates were harvested under non-denaturing conditions using 1X Cell Lysis Buffer. To affinity pre-
cipitate activated G-protein, spin cups were incubated with 100 mL of glutathione resin and subsequently washed with 1X Cell Lysis
Buffer. 20 mg of GST-PAK1-PBD was added to spin cups containing glutathione resin, after which 700 mL of the cell lysate containing
1mg total protein was added, and themixwas incubated at 4C for 1 hour with gentle shaking. Following threewasheswith 400 mL 1X
Cell Lysis Buffer, samples were eluted by adding 2X reducing sample buffer containing 200 mM DTT in 2X SDS sample buffer, and
subsequently heated for 5 min at 95C. 25 mL of eluted samples were loaded onto an SDS-PAGE gel for subsequent immunoblot
analysis using the provided Rac1 mouse monoclonal antibody (1:1000 dilution).
Immunohistochemistry analysis
10 mM thick sections were obtained from formalin-fixed and paraffin-embedded tumors and stained using an anti-phospho PKCz
Thr560 antibody (Abcam, ab62372) at a dilution of 1:100. For breast PDX and cell line-derived xenograft tumors, fresh frozen tumor
pieces were mounted on Optimal Cutting Temperature (OCT) compound and sectioned to 10 mM thickness. To assess the presence
of activated natural killer cells, slides were stained using goat anti-mouse NKp46/ncr1 polyclonal antibody (R and D systems, 170-
6516) at a final concentration of 3 mg/ml. Images were captured on a Hamamatsu NanoZoomer, and staining was quantified using the
IHC Profiler plug-in for ImageJ.
Proximity ligation assay
For the proximity ligation assay (PLA), all incubations were performed in a humidity chamber as per the manufacturer’s instructions
using a Duolink In Situ Detection Reagents Red kit (Sigma-Aldrich, DUO92008). Briefly, MCF10A PIK3CA isogenic cells were seeded
on glass coverslips, serum-starved overnight, and stimulated with full serum and growth factors for 30 min; control cells were un-
treated. They were then fixed with 4% paraformaldehyde (PFA), blocked and incubated with primary antibodies (anti-cPLA2 and
anti-phospho PKCz Thr560) for 1 hour at room temperature. Samples were then incubated with Minus and Plus PLA probes
(Sigma-Aldrich, DUO92004 and DUO92002) for 1 hour at 37C, followed by a ligation step for 30 min at 37C, and an amplification
step for 100min at 37C. Finally, the coverslips weremountedwith the Duolink PLAmountingmedia and DAPI, and fluorescence was
visualized with a Zeiss 710 Confocal microscope with a 40x oil objective. Images were analyzed using a custom MATLAB (2017b)
script. Briefly, the DAPI signal was segmented by taking a maximum intensity projection, smoothing, and then thresholding (Otsu,
1979). Borders between cells were estimated by finding the midpoints between nuclei using a watershed approach. A summed pro-
jection was calculated for the probe signal, this was smoothed (Gaussian kernel sigma of 1 pixel), and thresholded. The threshold
calculated from a positive control image was applied to all images. The segmented image of the probe was used to calculate the
number of foci on a per cell basis.
Fluorescent calcium assay
Calcium flux was measured using the Fluo-4 DirectTM Calcium Assay Kit (Thermo Fisher Scientific, F10471). Full MCF10A growth
medium was removed and replaced with FBS-free medium for 18 hours. Control cells were treated with equal volume of the cultureCell 181, 1596–1611.e1–e16, June 25, 2020 e14
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induced cells were stimulated with full media for 30 min, while incubated with the calcium assay reagent solution. Cells were then
analyzed by monitoring the fluorescence of the Fluo-4 dye using an ImageXpress Micro Confocal High-Content Imaging System
(Molecular Devices) and a 20x objective with 488 nm excitation. The fluorescence per field before and after induction was calculated
using a MetaXpress Software Custom Module.
To assess the effects of PLCg1 inhibition on calcium flux, cells were treated with either 2 mM U73122 for 24 hours, or transiently
transfected with 25 nMON-TARGETplus SMARTpool human siRNA targeting PLCg1 for 48 hours. For the final 18 hours, full MCF10A
growth medium was removed and replaced with FBS-free medium. Immediately prior to the assay, cells were treated with equal vol-
ume culture media and 2x Fluo-4 DirectTM calcium assay reagent, and baseline fluorescence wasmonitored using an ImageXpress
Micro Confocal High-Content Imaging System (Molecular Devices). After 300 ms, cells were induced by adding 1 mL full MCF10A
growth medium, and fluorescence of the Fluo-4 dye was monitored using a 20x objective with 488 nm excitation. Calcium flux
was calculated by first normalizing fluorescence readings to baseline measurements using the formula: dF = F(t) – F(0)/F(0), where
F = fluorescence at 488 nm, t = time, and F(0) represents the average baseline readings from 1-299 ms. Fluorescence values were
subsequently normalized to a unit interval between 0 and 1 and presented as the time required post stimulation to reach a maximal
calcium intensity.
Quantitative RT-PCR and PIK3CA mutation analysis
RNA was extracted using the RNeasy Plus Mini Kit (QIAGEN, 74134) and 1 mg of total RNA was used to synthesize complementary
DNA (cDNA) using the QuantiTect Reverse Transcription Kit (QIAGEN, 205311). Primer sequences used are as follows: Human
cPLA2, forward: 50-GATGAAACTCTAGGGACAGCAAC-30,
reverse: 50-CTGGGCATGAGCAAACTTCAA-30, Human b-actin: forward: 50-GACCCAGATCATGTTTGAGACC-30,
reverse: 50-CTTCATGAGGTAGTCAGTCAGG. Reactions were performed with SYBR Select Master Mix (ThermoFisher, 4472908)
using the TProfessional Thermocycler from Biometra and analyzed with the qPCRsoft version 3.1 (Thistle Scientific/Analytik Jena).
The following cycle reactions were used: pre-denaturation for 3min at 95C, followed by 45 cycles of 5 s at 95C (denaturation), 5 s at
55.8C (annealing) and 15 s at 72C (elongation).
To detect PIK3CA mutations in primary breast tumor samples, DNA was extracted from 10 mg of tissue using the QIAamp DNA
mini kit (QIAGEN, 51304). Mutations in exon 9 (helical domain) and exon 20 (kinase domain) of PIK3CAwere assessed using the PNA-
Clamp PIK3CAMutation Detection Kit (Panagene, PNAC-4001), according to themanufacturer’s instructions. Briefly, reactions were
performed using 10 ng DNA with a SYBR Green PCR reaction premix and primer premixes detecting E542, E545, Q546 and H1047
mutations using the TProfessional Thermocycler. The following cycle reactions were used: pre-denaturation for 5 min at 94C, fol-
lowed by 40 cycles of 30 s at 94C (denaturation), 20 s at 70C (peptide nucleic acid clamping), 30 s at 63C (annealing) and 30 s
at 72C (extension). PIK3CA mutations were assessed based on manufacturer’s instructions.
In vitro kinase assay
In vitro kinase assays were performed using the ADP-Glo Kinase Assay (Promega, V6930), according to the manufacturer’s instruc-
tions. Briefly, 100 ng recombinant human protein kinase C zeta (PKCz, Insight Biotechnology, TP302472) and 0.5 mg/ml phospholi-
pase A2, group IVA (cPLA2, Insight Biotechnology, TP320972) were incubated in kinase buffer comprising 40mMTRIS buffer pH 7.5,
20 mMMgCl2 (Sigma-Aldrich, M8266), 0.1 mg/ml BSA (Sigma-Aldrich, A2153) and 50 mMDTT (Sigma-Aldrich, 646563), and supple-
mented with 20 mM ATP. Reactions were incubated at 30C for 3 hours, after which luminescence was measured following an inte-
gration time of 1 s.
Chemokine assays
Tumor samples were placed in 2 mL lysing tubes prefilled with 1.4 mm ceramic (zirconium oxide) beads and 1 mL of chilled PBS.
Samples were homogenized with a Precellys24 homogenizer programmedwith three 30 s cycles at 6,500 Hz and 4-min pause times.
At the end of the homogenization cycle, samples were centrifuged at 5,000rpm for 10 min at 4C, and supernatants were transferred
to fresh Eppendorf tubes
To measure CCL5 (RANTES) chemokine levels, the CCL5 Mouse ELISA kit (Abcam, ab100739) was used according to the man-
ufacturer’s instructions. Briefly, 100 mL of standards prepared in Assay Diluent A and sample supernatantswere added to appropriate
wells and incubated at room temperature for 2.5 hours. Wells were subsequently washed 4 times with 1XWash Solution, and 100 mL
of 1X Biotinylated CCL5 (RANTES) Detection Antibody was added and incubated for 1 hour at room temperature with gentle shaking.
Following the incubation with the detection antibody, wells were washed 4 times and incubated with 100 mL HRP-Streptavidin so-
lution for 45 min at room temperature with gentle shaking. Following a final set of 4 washes, 100 mL of TMB One-Step Substrate Re-
agent was added to each well and incubated for 30 min at room temperature in the dark with gentle shaking. 50 mL of stop solution
was subsequently added, and measurements were taken immediately at 450 nm.
To measure CX3CL1 chemokine levels, the CX3CL1 Mouse ELISA kit (Abcam, ab100683) was used according to the manufac-
turer’s instructions. Briefly, 100 mL of standards prepared in Assay Diluent C and sample supernatants were added to appropriatee15 Cell 181, 1596–1611.e1–e16, June 25, 2020
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of 1X Biotinylated CX3CL1 Detection Antibody was added and incubated for 1 hour at room temperature with gentle shaking.
Following the incubation with the detection antibody, wells were washed 4 times and incubated with 100 mL HRP-Streptavidin so-
lution for 45 min at room temperature with gentle shaking. Following a final set of 4 washes, 100 mL of TMB One-Step Substrate Re-
agent was added to each well and incubated for 30 min at room temperature in the dark with gentle shaking. 50 mL of stop solution
was subsequently added, and measurements were taken immediately at 450 nm. All measurements were normalized to total protein
content as determined using the BCA protein assay (Thermo Fisher Scientific, 23225).
Lipid extraction and eicosanoid profiling
Total lipids were extracted based on the Bligh and Dyer method (Bligh and Dyer, 1959) and analyzed as described previously (Wolfer
et al., 2015). Briefly, cell lines were harvested when 80% confluent, and media was replaced one hour prior to lipid extraction. Cell
pellets were resuspended in 1ml water, after which 3.75 mL chloroform/methanol mixture (1:2 v/v) was added and samples were
vortexed and incubated for at least 30 min on ice. 1.25 mL chloroform was added, followed by 1.25 mLmili-Q water and after vortex-
ing and centrifugation at 1000rpm for 10min at 4C, the organic bottom phasewas separated and transferred to a 15mL amber vial to
get dried under a nitrogen flow. For conditionedmedia profiling, cells were grown to 80%confluency in full media, after which residual
media was washed off twice with PBS, and cells were cultured with FAF media for 48 hours. The conditioned media was centrifuged
at 2000 g for 20 min to remove cell debris. Samples were concentrated using a centrifugal vacuum evaporator. The lipid extraction
was then performed as above.
Eicosanoid levels were determined using liquid chromatography with a Waters HSS T3 UPLC column connected to aWaters Xevo
TQ-S triple quadrupole mass spectrometer with an electrospray ionization (ESI) source. TargetLynx (Waters, Manchester, UK) was
used for peak detection and integration. Data was normalized to protein concentration.
To measure PGE2 (Enzo Life Sciences, ADI-900-001) and AA (Generon, CEB098Ge) concentrations, enzyme-linked immunosor-
bent assays were used, following the manufacturer’s instructions.
Bioinformatic analysis
Gene-centric RMA-normalized expression data and mutation status for available cell lines were obtained from the Cancer Cell Line
Encyclopedia (CCLE). 150 frequently mutated genes were identified based on a mutation frequency ofR 20% or higher in n = 35
available cell lines, and significant enrichment in observed clusters was assessed using Fisher’s exact test. A functional annotation
analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID, v6.8) (Huang et al., 2009) was used to
identify biologically relevant pathways represented by a set of 512 genes, which were significantly upregulated in the PIK3CA mu-
tation- and lipid-enriched cluster. Interactions between genes involved in the identified pathways were visualized by functional
gene networks using the ‘ReactomePA’ package in R (Yu and He, 2016).
QUANTIFICATION AND STATISTICAL ANALYSIS
Student t test, Fisher’s exact test, and one- or two-way ANOVA were used to evaluate statistical significance as indicated in the
respective figure legends. The Shapiro-Wilk test was used to assess normality. The ‘N’ for each experiment can be found in the figure
legends and represents independently generated samples for in vitro experiments, wells for cell-based assays, or mice for in vivo
experiments. Bar graphs present the mean ± standard error of the mean (SEM). Significance was defined as p < 0.05, and denoted
by asterisks throughout the figures as follows: n.s (not significant), *(p < 0.05), **(p < 0.01), ***(p < 0.001). No statistical methods were
used to determine sample size, and no completed data were excluded from the analysis performed in this manuscript. Statistical
tests were performed using GraphPad Prism (version 8.0.1) and R statistical software (version 3.5.1).Cell 181, 1596–1611.e1–e16, June 25, 2020 e16
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Figure S1. Related to Figure 1
(A) Volcano plots of significantly altered phospholipids between receptor positive and negative cell lines. Black dots: not significantly altered; Red dots:
significantly upregulated; Green dots: significantly downregulated phospholipids. (B) Area under the curve (AUC) classification accuracies for estrogen (ER),
progesterone (PR), HER2 receptor and triple negative status of 30 primary and PDX breast tumors (median intensity of n = 3 separate sections per tumor) following
feature selection for phospholipids in the m/z range 600-900 and leave-one-out cross validation. (C) Immunoblot analysis of estrogen inducible protein pS2 (top)
and prediction of ESR1 expression (bottom) in ER+ve T47D cells following treatment with 0.1% DMSO or indicated concentrations of 4-OHT for 72 hours using
REIMS. (D) NMF consensus maps summarizing the clustering of cell lines used in Figure 1D. The color map represents the correlation between cell lines in the
same cluster when samples are divided into 2-6 groups. The highest cophenetic score was obtained for two clusters. (E) REIMS analysis of MCF10A PIK3CAWT
and MUT cells cultured as 3D spheroids for 10 days. Clustering was performed as in Figure 1D using the median lipid intensities of 3 biological replicates. (F)
Overall, precision and recall classification accuracies for PIK3CA mutation status in primary and PDX breast tumors (n = 30 in total), using all detectable lipid
features (n = 1147) following 3-fold cross validation repeated 100 times with random forest as a classifier. n.s., not significant; *p% 0.05; **p% 0.01; ***p% 0.001.
P values in (C, bottom panel) were calculated with one-way ANOVA, followed by unpaired, two-tailed Student’s t test with Bonferroni correction.
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Figure S2. Related to Figures 1 and 2
(A) Pathway enrichment analysis of genes corresponding to the three most significantly enriched KEGG pathways determined from the 512 significantly upre-
gulated genes in the lipid-enriched cluster from Figure 1D. (B) Gene interaction networks corresponding to the 55 genes encompassing the KEGGpathways in (A).
(C) FASN, (D) ELOVL6, and (E) LDLRAP1mRNA expression between cell lines in the lipid-enriched (n = 19) and depleted (n = 15) clusters. *p% 0.05; **p% 0.01;
***p% 0.001. P values in (C), (D), and (E) were calculated with unpaired, two-tailed Student’s t test.
ll
OPEN ACCESSArticle
AB C
Figure S3. Related to Figure 2
(A) Cell viability of MCF10A PIK3CA MUT cells following treatment with increasing concentrations of rapamycin, torin 1, BYL-719, BKM120, MK2206 or
GSK690693 for 72 hours. (B) Unsupervised hierarchical clustering of the median phospholipid intensities of 5 PIK3CAMUT breast cancer cell lines (MCF7, T47D,
MDAMB361, MDAMB453 and BT474) treated with 20 nM rapamycin, 100 nM BYL-719 and 150 nM MK2006 for 72 hours. (C) Immunoblot analysis of mTORC1
and mTORC2 signaling in the PIK3CAMUT isogenic panel. Cells were serum and growth-factor starved for 16 hours and subsequently stimulated with 5% horse
serum, 20 ng/ml EGF, 0.5 mg/ml hydrocortisone and 10 mg/ml insulin for 30min. Data in (A) are presented as themean ±SEM of n = 4 biological replicates and are
representative of at least two independent experiments. n.s., not significant; *p % 0.05; **p % 0.01. P values in (A) were calculated with unpaired, two-tailed
Student’s t test.
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Figure S4. Related to Figures 3 and 4
Intracellular levels of (A) Arachidonic acid (AA) and (B) PGE2 levels as measured by LC-MS profiling. (C) AA levels from the conditioned media (CM) of indicated
cells before and after lipid depletion (LD). (D) Cell proliferation assays of MCF10A PIK3CAWT cells cultured in CM derived fromWT or E545KMUT cells before or
after LD, with or without the supplementation of 25 mMAA, palmitate or palmitoleate. (E) Cell proliferation assays of MCF10A PIK3CA E545K MUT cells before or
after LD, with or without the supplementation of 25 mM AA, palmitate or palmitoleate. (F) Diacylglycerol (DAG) levels in MCF10A PIK3CAWT and MUT cells. (G)
Diagram summarizing DAG contribution to AA production. Sulforhodamine B (SRB) protein staining was used in (D) and (E) to measure cell proliferation over
5 days. Data are presented as the mean ± SEM of n = 3-4 biological replicates and are representative of at least two independent experiments. *p% 0.05; **p%
0.01; ***p % 0.001. P values in (A), (B), (C) and (F) were calculated using one-way ANOVA followed by unpaired, two-tailed Student’s t test with Bonferroni
correction, and in (D) and (E) with two-way ANOVA.
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Figure S5. Related to Figure 4
(A) Immunoblot of phospholipases in MCF10A PIK3CAWT andMUT cells following serum and growth-factor deprivation for 16 hours and stimulation with serum
and growth factors for 30min. (B) Immunoblot analysis of cPLA2 protein decay following treatment with 50 mMcycloheximide (CHX) for the indicated times. Image
and quantification is from one experiment. (C) Real-time quantitative PCR of PLA2G4A expression in theMCF10A PIK3CA isogenic panel. (D) AA levels measured
by REIMS in MCF10A E545K PIK3CAMUT cells following RAPTOR and RICTOR siRNA-mediated knockdown 48 hours post transfection under exogenous FAF
conditions. ELISA analysis of (E) AA and (F) PGE2 in the MCF10A PIK3CA isogenic panel 48 hours post RICTOR siRNA-mediated knockdown. (G) Immunoblot
analysis of cPLA2 protein decay (top) and quantification (bottom) following RICTOR siRNA-mediated knockdown and treatment with 50 mMcycloheximide for the
indicated times. Image and quantification is from one experiment. (H) Immunoblot analysis of substrates of conventional PKCa/b (p-IkBaSer32 and p-RB Thr821/
826), novel PKCε (p-STAT3 Ser727 and p-PKD Ser744/748) and atypical PKCz (p-RKIP Ser153 and p-cPLA2 T376) isoforms following treatment of MCF10A
E545K andH1047RMUT cells with 1 mMof each PKCa, b, ε, and z peptide inhibitors for 72 hours. (I) Enzymatic activity of cPLA2, iPLA2, and sPLA2 in theMCF10A
PIK3CA isogenic panel following treatment with 100 nM ASB14780 for 72 hours. (J) AA levels measured by REIMS in MCF10A E545K MUT cells treated with
100 nM ASB14780, 1 mM each of PKCa, b, ε, and z peptide inhibitors, 250 mMGSK650394, or 150 nMMK2206 for 72 hours under exogenous FAF conditions. (K)
Immunoblot (right) of total PKCz and phospho-S505 and T376 cPLA2 of MCF10A PIK3CAWT and MUT cells following PKCz siRNA-mediated knockdown, and
cPLA2 activity (left) following 48 hours post-transfection. (L) Representative phospho-PKCz Thr560 immunoreactivity images (left) of 9 PIK3CAMUT (blue) and 9
WT (red) breast PDX tumors. Scale bar = 250 mm. Quantification of percent positive regions (right) was performed using the IHC profiler plug-in for ImageJ. Data
are presented as the mean ± SEM of n = 3-5 biological replicates and are representative of at least two independent experiments. n.s., not significant, *p% 0.05;
**p% 0.01. P values in (C), (D), (E), (F), (I), (J) and (K, right) with one-way ANOVA followed by unpaired, two-tailed Student’s t test with Bonferroni correction, and in
(L) with unpaired, two-tailed Student’s t test.
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Figure S6. Related to Figures 4 and 5
(A) Immunoblot analysis of phospho-Tyr783 PLCg1 in MCF10A PIK3CA isogenics following serum and growth factor deprivation for 16 hours, and stimulation
with serum and growth factors for 30min. Densitometry values are either scaled to unstimulated or stimulated (bold)WT samples. (B) Measurement of intracellular
calcium flux in MCF10A PIK3CA isogenics following serum and growth factor deprivation and stimulation for 30 min. (C) Immunoblot of MCF10A PIK3CAWT and
MUT cells following siRNA-mediated knockdown of PLCg1. (D) Intracellular calcium flux of MCF10A PIK3CAWT (top), E545K (middle) and H1047R (bottom) cells
(legend continued on next page)
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48 hours post transfection with siPLCg1, or (E) treatment with 2 mM U73122 for 24 hours. For the final 18 hours of the treatments, cells were serum and growth
factor deprived, and stimulated with full media immediately prior to the assay. cPLA2 activity in MCF10A PIK3CA WT and MUT following (F) siRNA-mediated
knockdown of PLCg1 for 48 hours, or (G) treatment with 2 mM U73122 for 24 hours. (H) AA levels measured by REIMS in MCF10A PIK3CA isogenics following
treatment with 2 mM U73122 for 24 hours. (I) Representative confocal images and (J) quantification of in situ proximity ligation assay (PLA) between cPLA2 and
phospho-Thr560 PKCz in MCF10A PIK3CAWTandMUT cells. (K) Immunoblot analysis of phospho-cPLA2 (T376) custom antibody in theMCF10A isogenic panel
following serum and growth factor deprivation for 18 hours and subsequent stimulation for 30 min (left), treatment with 1 mM PKCz peptide inhibitor for 72 hours
(middle), and in MCF10A H1047R cPLA2 CRISPR knockout cells overexpressing a phosphoresistant mutant (T376A) cPLA2 (right). (L) Activity of cPLA2 in
MCF10A PIK3CA WT or H1047R cPLA2 CRISPR knockout cells transfected with 9 mg of either WT-cPLA2, or S505A/T376A phosphoresistant mutant cPLA2
constructs. Activity was measured 48 hours post-transfection. Cell proliferation of MCF10A (M) PIK3CAWT and (N) E545KMUT cells expressing control shGFP,
cPLA2-sh1 or sh5 under exogenous FAF conditions. Sulforhodamine B (SRB) protein staining was used to measure cell proliferation over 5 days. Data in (B), (D),
(E), (F), (G), (H), (L), (M) and (N) are presented as the mean ± SEM of n = 3-6 biological replicates and are representative of at least two independent experiments.
n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001; P values in (B), (D), (E), (M) and (N) were calculated using two-way ANOVA. One-way ANOVA followed by
Student’s t test with Bonferroni correction was used for (F), (G), (H), (J)and (L).
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ll
OPEN ACCESS Article
Figure S7. Related to Figures 6 and 7
(A) Relative tumor growth and (B) tumor weights of CAL51 (PIK3CA MUT)-derived xenografts stably expressing control shGFP or two independent shRNAs
targeting cPLA2 (cPLA2-sh1 and cPLA2-sh5) in mice fed a balanced omega3:omega6 diet. (C) Relative tumor growth and (D) tumor weights of Hs578T (PIK3CA
WT)-derived xenografts stably expressing control shGFP or cPLA2-sh1 or cPLA2-sh5 in mice fed a balanced omega3:omega6 diet. AA levels measured by
REIMS in (E) PIK3CA MUT (CAL51) and (F) PIK3CA WT (Hs578T) snap frozen excised tumors. AA intensities are reported as scaled values to the appropriate
shGFP-fat free diet control. Quantification of CCL5 from excised tumors derived from (G) PDX and (H) cell line-derived xenograft studies. Quantification of
CX3CL1 from excised tumors derived from (I) PDX and (J) cell line-derived xenograft studies. Concentrations of chemokines in (G-J) were determined fromwhole
tumor lysates using ELISA, and normalized to protein content. (K) Representative immunohistochemical staining of the activatedNK cell marker NKp46 in BR1282
(PIK3CA MUT) and BR1458 (PIK3CA WT) PDX tumors. (L) and (M) Quantification of positively immunostained areas from (K). (N) Representative immunohis-
tochemical staining of NKp46 in shGFP, cPLA2-sh1 and cPLA2-sh5 expressing CAL51 (PIK3CAMUT) and Hs578T (PIK3CAWT)-derived xenograft tumors under
fat free or ‘Western’ diets. (O) and (P) Quantification of positively immunostained areas from (N). Data in (A), (C), and (E) to (J) are presented as the mean ± SEM of
n = 3–5 mice for cell line xenograft or n = 7–8 mice for PDX studies. n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001; P values in (A) and (C) were calculated
using two-way ANOVA, and one-way ANOVA followed by unpaired, two tailed Student’s t test with Bonferroni correctionwas used in (B), (D), (E), (F), (G), (H), (I), (J),
(L), (M), (O), (P).
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